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Abstract 
 
The β2 integrin subfamily are cell surface glycoproteins expressed mainly on 
leukocytes and mediate cell-cell adhesion and cell-matrix interactions. They have 
four distinct α subunits (CD11a, b, c and d) which associate with the β2 (CD18) 
subunit (Mazzone & Ricevuti, 1995). The α-subunits contain an inserted (I) domain 
which together with the β-subunit I-like domain are proposed to be involved in ligand 
binding (Gahmberg et al., 2009). It has been found that the integrins recognize a 
tripeptide argininyl-lysinyl-cysteine (RKC) motif present in CD23 and that the β-
subunit is involved in binding via this motif (Borland et al., 2007). The binding 
characteristics of integrins are of great clinical interest due to their involvement in 
defective embryogenesis, blood coagulation, osteoporosis, acute renal failure, 
retinopathy, cancer and inflammation.  
 
Using CD23 as model ligand, the binding between the molecules was investigated 
via the production of recombinant protein domains.  Bacterial expression vectors 
were prepared for the CD11b I-domain, CD18 I-like domain, CD23 and a site-
directed double mutant of CD23 (RKCΔAAC). Proteins were expressed in E. coli 
BL21 (DE3) cells via induction with IPTG, and harvested via centrifugation following 
sonication. Soluble CD11b and CD18 proteins were purified using a GST Spin 
Purification Kit (Pierce). CD23 proteins were refolded via rapid dilution and purified 
via gel filtration chromatography on Superdex 75 (Daniels et al., 2005). Purity of 
protein was assessed with SDS-PAGE. CD18 was expressed in very low 
concentrations in the supernatant and was therefore produced in insufficient quantity 
for further study. 
 
Equilibrium dissociation and kinetic rate constants were determined by surface 
plasmon resonance spectroscopy on a ProteOn XPR36.  NLC and GLC chips were 
used to immobilize CD11bα-I domain as the ligand via biotinylation and amine 
coupling, respectively. Analytes included 16kDa derCD23, 25kDa WT CD23 and 
25kDa mutant CD23 (RKΔAA) at varying concentrations. Integrin interactions with 
ligands requires a conformational change in the integrin from a closed low affinity 
state to an open high affinity state (Xiong et al., 2013).  The SPR data of the CD11b 
  ii 
 
α-I domain interaction with CD23 concurs, showing an initial fast association with the 
low affinity state of CD11b, followed by a slow off-rate in the high affinity state.  
Mutation of the RKC motif causes a faster rate of high affinity reversion (kd2) which 
suggests that the mutant binds better to the low affinity state of CD11b I-domain. KD 
values obtained for the interaction between CD11b I-domain and mutant CD23, as 
well as wild type CD23 in the presence or absence of metals (Mg2+ and Ca2+), were 
31.9 nM, 51.6 nM and 71.0 nM, respectively, suggesting a high affinity interaction. 
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1 INTRODUCTION AND LITERATURE REVIEW 
 
1.1 Integrins: Biological and Clinical Relevance 
 
The integrin family consists of heterodimeric membrane-bound glycoproteins that 
mediate cell-cell adhesion and cell-matrix interactions in a broad range of biological 
functions which includes recruitment of leukocytes to inflammatory sites, stimulation 
of interleukin-1β production as well as cellular activation (Rezzonico et al., 2000).  
 
In mammals, 18 α and 8 β subunits combine to form 24 integrins (Arnaout et al., 
2002). The integrins have been organized into eight distinct families based on their β 
subunit associations. Figure 1.1 illustrates the integrin superfamily and indicates the 
relative pairing of α and β subunits. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: The integrin superfamily. The family comprises 18α and 8β subunits that have 
been identified. The β2 integrins are encircled and highlighted (Gahmberg et al. 2009). 
 
In normal, healthy individuals, serum integrin levels are minimal. However, integrin 
alterations are responsible for a number of pathological manifestations such as 
defective embryogenesis, blood coagulation, osteoporosis, acute renal failure, 
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retinopathy and cancer. Pharmacological, molecular and genetic evidence 
demonstrate that tumour progression is angiogenesis-dependent. Integrins 
associated with cell adhesion mechanisms, and which facilitate migration and 
invasion through the extracellular matrix, are critical to the growth of new blood 
vessels and are thus involved in angiogenesis. αvβ3 receptors are expressed mainly 
on the surface of endothelial cells predominantly during angiogenesis, making it a 
compelling target for agents within the vascular space. In addition, the αvβ3 integrin is 
over-expressed on proliferating tumour endothelial cells and has been used in a 
recent study by Eldar-Boock et al., (2011) to actively and selectively target the 
chemotherapeutic drug paclitaxel (PTX) to tumour cells and their surrounding tumour 
endothelial cells via binding to the αvβ3 integrin receptor. 
 
The β2 integrin subfamily are cell surface glycoproteins that have four distinct α 
subunits (CD11a, b, c and d) which associate with the β2 (CD18) subunit (Mazzone 
& Ricevuti, 1995). The β2 integrins are expressed mainly on leukocytes and include: 
 
 leukocyte function-associated antigen-1 (LFA-1 or CD11a/CD18) 
 Mac-1 (αMβ2 or CD11b/CD18),  
 p150,95 (αXβ2 or CD11c/CD18) and  
 αDβ2 (CD11d/CD18).   
 
The leukocyte integrins mediate a range of adhesive interactions that are essential 
for normal immune and inflammatory responses, such as spreading, adhesion, 
chemotaxis, migration, respiratory burst and phagocytosis (Lu et al., 1998; Choi & 
Nham, 2002). 
 
The β2-integrin ligand binding characteristics are important to study because of the 
role these molecules play in the strong adherence of leukocytes to the endothelium, 
the transendothelial leukocyte migration at inflammatory sites and in the activation 
and proliferation of T cells in the mucosa. This is particularly evident in Crohn’s 
disease, a transmural inflammatory disease that affects both the large and small 
intestine. Although the pathogenesis of Crohn’s remains unclear, there is a marked 
increase in the number of activated lymphocytes in the intestine and therefore the 
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prevalence of associated integrin CD11b/CD18. The increased expression of these 
molecules may have implications for therapeutic interventions in Crohn’s disease 
(Bernstein et al., 1998). 
 
There are at least three inherited autosomal recessive diseases in humans which 
involve mutations in genes coding for integrins. The bleeding disorder Glanzmann 
thrombasthenia is caused by mutations in either the α or β subunit of the platelet 
integrin, αIIbβ3. Secondly, it is now recognised that one of the variants of the usually 
lethal skin blistering disorder, epidermolysis bullosa (JEB-PA.), is caused by 
mutation in either the α or β subunit of the epithelial hemidesmosome integrin, α6β4. 
Many of the mutations cause defective αβ heterodimer formation. The majority of the 
β subunit mutations are in the conserved N-terminal region known as the β I-like 
domain. Leukocyte adhesion deficiency-1 (LAD-1) is the result of mutations in the β2 
subunit of the CD11/CD18 integrins, LFA-1, Mac-1 and p150,95. The classical 
disease characteristics are recurring necrotic soft tissue infections, impaired wound 
healing with lack of ‘pus’ and severe gingivitis. The disorder is viewed primarily as a 
failure of neutrophil function because these cells are essential first arrivals at sites of 
tissue injury and, importantly, they rely most heavily on β2 integrins because they 
lack significant levels of other integrins (Hogg & Bates, 2000). 
 
The majority of LAD-1 cases involve single point ‘missense’ mutations in the β2 
subunit gene giving rise to an altered precursor protein which then fails to bind to the 
α subunit precursor. Most of these mutations are in the 240-residue β I-like domain, 
which is highly conserved in all β subunits. Generally, the hallmark of LAD-1 is the 
absence or greatly reduced expression of β2 integrins, but Hogg and Bates (2000) 
describe a patient with LAD-1 who, despite expressing ~60% β2 integrins, had a 
mutation within the β I-like domain which allowed normal expression but no β2 
integrin function. The mutated amino acid (S138P) contributes to the metal ion 
dependent adhesion site (MIDAS) in the βI-like domain, establishing the importance 
of this motif in the β2 subunit for integrin function in vivo (Hogg and Bates, 2000). 
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1.2 Interactions of β2 Integrins 
 
Integrins are also the focus of extensive clinical research, because of their crucial 
involvement in numerous disease states. However, the extent within which we 
understand the structural basis for these interactions varies among different integrin–
ligand pairs, because of the limited number of high-resolution crystal structures thus 
far determined. Although direct structural determination is the most straightforward 
way to gain insights into the molecular mechanisms underlying recognition, recent 
advances in the biochemical characterization of integrin–ligand interactions using 
purified recombinant proteins (as opposed to more conventional cell adhesion 
assays) have contributed to unravelling some of the unexpected binding modes used 
by various integrin–ligand pairs (Takagi, 2007). 
 
Integrins bind to a considerable number of cell membrane proteins and extracellular 
matrix molecules. In general, the β2 integrin ectodomains interact with more than 30 
extracellular ligands where the best characterised integrin ligands are the Ig 
superfamily members, including vascular cell adhesion molecule (VCAM-1) and the 
intracellular adhesion molecules (ICAMs). The leukocyte-specific CD11/CD18 
integrins, especially CD11a, bind to ICAMs such as ICAM-1, ICAM-2, and ICAM-3 
(Yalamanchili et al., 2000). CD11b also binds to ICAM-1, as well as to several 
soluble ligands, including the complement fragment iC3b, fibrinogen, coagulation 
factor X, and LPS (Diamond et al., 1993). CD11c binds many ligands such as 
collagen type 1, iC3b, fibrinogen, LPS and possibly ICAM-1 (Nham, 1999 and 
Arnaout, 2009). Compared with CD11a and CD11b, the ligands and functional role of 
CD11c is less well functionally characterized, but appear to be similar to those of 
CD11b (Rezzonico et al., 2000). Furthermore, according to Lecoanet-Henchoz et al. 
(1995) it has been reported that CD11b/CD18 and CD11c/CD18 can exhibit an 
additional adhesive function because of their ability to bind the low affinity receptor 
for IgE, CD23, (refer section 1.4).  
 
The short cytoplasmic tail of CD18 interacts with several proteins, including: 
cytoskeletal proteins such as kindlin 3, talin, filamin and α-actinin, signalling proteins 
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such as cytohesin-1, focal adhesion kinase and protein kinase D and adaptor 
proteins such as JAB-1 and 14-3-3 proteins (Arnaout, 2009 and Gahmberg et al., 
2009).  
 
It should be noted that some integrins tend to show a high specificity for certain 
ligands whereas others tend to bind several different types of ligands. According to 
Gahmberg et al. (2009), a key observation was the identification of anargininyl-
glycinyl-aspartic acid (RGD) motif, identified in fibronectin and various other proteins, 
which acts as a common recognition site for integrins. However, integrins are known 
to bind to proteins via other peptide motifs which usually results in improvement of 
the outcome of occupation of the RGD site (Borland et al., 2007). Furthermore, 
according to Borland et al., (2007), it was found that CD23 derived arginine-lysine-
cysteine (RKC) containing peptides interacted specifically with the β chains of the αV 
integrin family and not with the α-chain(discussed in section 1.4.3) although this is 
understandable considering the fact that αV-integrins do not contain an I-domain in 
their α-chains. 
 
1.3 Structure of β2 Integrins 
 
Association of the α and β2 subunit precursors occurs in the Golgi apparatus, and the 
assembled receptors are then transported to the cell surface or to intracellular 
stores. The α subunit has a long extracellular domain, a transmembrane domain and 
a short cytoplasmic domain. The β2 subunit has a highly conserved cysteine-rich 
region (CRR) which gives it a rigid tertiary structure. The divalent cations Ca2+ and 
Mg2+ are essential in the function and stabilization of the α/β2 complex (Mazzone & 
Ricevuti, 1995).   
 
Integrins can communicate over the plasma membrane resulting in their activation or 
deactivation. Adhesion may be regulated both by conformational changes in the 
integrin as well as valency changes (integrin clustering). Figure 1.2 shows integrin 
architecture and conformational changes associated with affinity regulation, 
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organization of domains within the primary structures and conformational change of 
integrins lacking an I domain (b) or containing an α-I domain (c).  
 
There are three overall integrin conformational states. The bent conformation has a 
closed headpiece and is low affinity. Extension at the α-knee and β-knee releases an 
interface between the headpiece and lower legs and yields an extended-closed 
conformation also with low affinity. Swing-out of the hybrid domain at its interface 
with the β-I domain is connected through the β-I α7-helix to rearrangements at the β-
I interface with the β-propeller domain (Figure 1.2b). This increases affinity for ligand 
in the extended-open conformation by ~1000-fold. Similar interdomain 
rearrangements in α-I integrins (Figure 1.2c) result inactivating a binding site for an 
internal ligand, Glu310, which pulls down the α-I α7-helix to activate a similar 
increase in affinity (~1000–10,000-fold), as shown by the LFA-1 α-I domain for the 
ligand ICAM-1. Although the integrin headpiece has highly preferred closed and 
open conformations, the lower β-legs are flexible, inferring ‘overall’ conformational 
states. This is symbolized by the ‘segmented’ lower β-leg. Therefore, only very large 
separations between α and βtransmembrane domains can be transmitted through 
the flexible β-leg to stabilize the high-affinity, open headpiece conformation (Schurpf 
and Springer, 2011). 
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Figure 1.2: Integrin domains and conformational changes associated with affinity regulation. 
(a) Organization of domains within the primary structures. (b, c) Conformational change of 
integrins (b) lacking an αI domain or (c) containing an αI domain. The domains are shown 
with the same colour scheme as in (a) (Schurpf and Springer, 2011). 
 
 
  8 
 
Further investigation of the principles that ligand binding induces integrin headpiece 
opening and that the open headpiece corresponds to the high affinity state of 
integrins has been confirmed with crystallographic structures on whole integrins in 
the presence and absence of ligand. The large movement at the integrin knees upon 
headpiece opening is thought to be important for transmission of allostery, through 
long legs that are flexible, except when elongational force is applied in cell adhesion 
(Zhu et al., 2008; Springer and Dustin, 2012). Zhu et al., (2013) show a remarkable 
pathway for transmission of signals in a cell surface protein with an exceptionally 
complex and large structure. A movement of only 2 Å at the β1-α1 loop in the ligand 
binding site is transmitted, through an intricate shape-shifting pathway, a distance of 
40 Å across the β-I domain. A 10Å α7 helix movement, like that of a connecting rod 
in the β-I domain, causes the hybrid domain to swing out by pivoting at its other 
connection to the β-I domain. The length of the hybrid domain is 40 Å, and the PSI 
and I-EGF1 domains attached at the end opposite the β-I domain make the total 
length of the upper integrin β leg ~70 Å. The ‘lever-like’ swing of the upper leg 
amplifies the 2Å movement of the β1-α1 loop to a 75Å increase in separation at the 
integrin knees (Figure 1.2). In this way the integrin headpiece appears designed for 
the complex job of transmitting allostery in extracellular environments. If in general, 
the open headpiece is the high affinity state of integrins, induction by inside-out 
signals of headpiece opening can be a general mechanism for integrin activation on 
cell surfaces and for allowing ligands to bind (Zhu et al., 2013, Schurpf and Springer, 
2011).  
 
In ligand binding in αI-less integrins, the open state of the β-I domain MIDAS Mg2+ion 
coordinates the Asp sidechain in ligands such as RGD (Luo et al., 2007; Springer et 
al., 2008). In contrast to such binding to an extrinsic ligand, the β-I MIDAS of αI 
integrins may bind an intrinsic ligand, that is to an invariant Glu residue that 
corresponds to the first residue in the αI C-linker, αX Glu-318 (Figures8.1.2 A and B 
in Supplementary figures). Mutation of this Glu abolishes integrin activation (Huth et 
al., 2000; Alonso et al., 2002). In contrast, when mutation of this Glu to Cys is 
combined with mutation of β2-I MIDAS-loop residue Ala-210 to Cys, an intersubunit 
disulfide bond forms, and ligand binding is constitutively activated (Yang et al., 
2004).  
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1.3.1 Characteristics of CD11b/c 
 
The α subunit of β2 integrins is responsible for binding extracellular ligands during 
inflammatory events and has 5 domains which are described in order from the N-
terminus to the C-terminus (Figure 1.3). The amino-terminal ~440 amino acids of α 
subunits within the β2 family contain seven sequence repeats which are folded into a 
β-propeller domain. This seven-bladed beta-propeller contains an inserted (I) domain 
between blades 2 and 3. The thigh domain is joined through a flexible ‘join’ to the 
calf-1 and calf-2 domains and then to a transmembrane and a cytoplasmic domain 
(Springer, 1997, Gahmberg et al., 2009 and Xie, 2010).  
 
Figure 1.3: Schematic drawing of the LFA-1 integrin (CD11a). Note the inserted (αI) domain 
within the β-propeller. Repeats W1-7 with metal divalent cation binding sites indicated as 
stars (Mg2+ in red and Ca2+ in green) within the β-propeller (Gahmberg et al, 2009). 
 
Divalent metal cations such as Ca2+ and Mg2+ are required for binding of the 
integrins to their ligands. Alteration of the divalent cation composition in the medium 
can inhibit or enhance adhesion. Regions important for ligand binding have been 
localized to the N-terminal regions of both the α and β subunits. The N-terminal beta-
propeller, of the α chain, includes the seven repeats of about 60 amino acids in 
length. These contain FG (phenylalanyl-glycyl) and GAP (glycyl-alanyl-prolyl) 
consensus sequences and may be termed FG-GAP repeats (Springer, 1997). 
Putative Ca2+ binding motifs are present in FG-GAP repeats 5, 6 and 7 (Gahmberg 
et al., 2009). 
 
Nine of the eighteen α subunits, including the four within the β2 integrin family, 
contain an inserted (αI) domain, also known as the von Willebrand factor (A) domain 
in the α-chain. The αI domain serves as the primary ligand-binding site when 
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present. In integrins lacking the I domain in the α chain, the binding site consists of 
an association between the α and β chains (Gahmberg et al., 2009). The α-I domain 
is inserted between blades 2 and 3 of the αX (CD11c) β-propeller domain. The two 
linkers connecting the α-I and β-propeller domains are surprisingly flexible, and the 
α-I domain itself has no contact with the β-propeller and only a small contact with the 
specificity determining loop (SDL) of the β I-like domain. α-I and β-I domains have 
structurally homologous α/β folds, with a metal ion-dependent adhesion site (MIDAS) 
that binds a Mg2+ ion (Figure 8.1.1 in Supplementary figures).Three different 
conformations termed closed, intermediate, and open have been defined for α-I 
domains (Springer and Wang, 2004; Luo et al., 2007).  
 
1.3.2 Characteristics of CD18 
 
The β2subunit of integrins, known as CD18, forms a heterodimer with the α-subunits 
CD11. It consists of a PSI (plexin-semaphorin-integrin)-domain, a β I-like domain, an 
Ig-like hybrid domain, 4 epidermal growth factor (EGF)-like domains, a “β-tail”, a 
transmembrane domain and a cytoplasmic tail, illustrated in Figure 1.4 (Gahmberg et 
al.,  2009). 
 
Figure 1.4: Schematic drawing of the LFA-1 integrin β Subunit (CD18). The β-I-like domain is 
shown with metal divalent cation binding sites indicated as stars (Mg2+ in red and Ca2+ in 
green)(Gahmberg et al,  2009). 
 
The β2 subunit has a highly conserved cysteine-rich region (CRR) encompassing 
regions I-EGF-2, -3, and -4, which gives it a rigid tertiary structure (Mazzone & 
Ricevuti, 1995 and Dileepan et al., 2007). The CRR has been postulated to contain 
three or four repeating elements, each containing eight cysteine residues (Tan et al, 
2001).  
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Another interesting structural feature is the β chain I-like domain. Previous 
crystallographic studies have shown that in some integrins which lack the α chain I-
domain, the β I-like domain is the primary ligand binding site. It contains three metal 
binding sites (Figure 8.1.2in Supplementary figures): the MIDAS, the ADMIDAS 
(adjacent to the MIDAS), and the SyMBS (synergistic metal binding site) previously 
known as the LIMBS (ligand induced metal binding site). In the physiologic low 
affinity state, all three metal binding sites are occupied: the MIDAS by a magnesium 
ion, while the other two metal binding sites can be occupied by calcium ions. 
However, this result is in contrast with previous studies that showed only one metal 
present in the absence of a ligand (Xiong et al, 2002 and Zhu et al., 2013).  
 
The magnesium ion at MIDAS directly coordinates the aspartic acid residue of the 
argininyl-glycinyl-aspartic acid (RGD) ligands which would usually be electrostatically 
repelled by the anionic residues of the MIDAS itself. Besides its known regulatory 
role, the ADMIDAS calcium ion can be involved in ligand binding (Gahmberg et al, 
2009). 
 
1.4 Overview of CD23 
1.4.1 Structure and Function 
CD23, also known as the low-affinity receptor for IgE (FcεRII), is a 45kDa type II 
integral membrane protein belonging to the calcium dependent (C-type) lectin 
superfamily (Wurzburg et al., 2006; Gould and Sutton; 2008).  In the membrane form 
CD23 exists as a homotrimer. Each monomer contains a lectin domain that is 
connected to the membrane via a long α-helical stalk (Figure 1. 5). The formation of 
trimeric CD23 occurs primarily due to hydrophobic interactions between each stalk 
(Beavil et al., 2006); however, favourable electrostatic forces at the interface 
between each lectin domain further stabilize the association of monomers (Hibbert et 
al., 2005). The trimeric nature of membrane CD23 can be disrupted when it is 
digested by endogenous proteases (Wurzburg et al., 2006). This causes shedding of 
monomeric soluble CD23 (sCD23) from the membrane surface. The size of the 
released fragments depends on the proteolytic sites that are cleaved. The 37, 33, 29, 
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25, and 16 kDa forms are most commonly generated, all of which contain the lectin 
domain (Conrad, 1990). 
 
 
Figure 1.5: The structure of human CD23. (A) Schematic representation of a CD23 
monomer. The head/lectin domain, α helical stalk, C-terminal tail, and N-linked glycosylation 
site of CD23 is illustrated. Hydrophobic amino acids that form part of the trimerization 
interface are coloured blue. Sites recognized by proteases are illustrated in dark blue.  The 
resulting soluble forms of CD23 and their corresponding sizes are also illustrated. Disulphide 
bridges are shown in pink and a reverse RGD sequence is shown in red (adapted from 
Beavil et al., 2006). (B) A three dimensional representation of one of the CD23 head domain 
regions, indicating binding regions for IgE-Fc, CD21 (situated adjacent to the C-terminal tail) 
and the αvβ5–integrins, situated in the N-terminal region close to the connection to the stalk. 
The NMR structure is illustrated in blue (PDB ID: 1T8D) and the X-ray crystal structure is 
shown in red (PDB ID: 2H2T) – but only the regions where the two structures differ most are 
superimposed (Hibbert et al., 2005 and Wurzburg et al., 2006). The single Ca2+ ion observed 
is shown as a sphere in its respective colour (Gould & Sutton (2008). (C) CD23 C-type lectin 
domain (PDB ID: 4G9A) showing the R172 and K173 within the RKC motif, (refer to section 
1.4.3) rendered, oriented and labelled using PyMol v1.6.  
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1.4.2 Role of CD23 in inflammation and allergies 
 
CD23 is present on many cell types including B cells, activated T cells, monocytes, 
eosinophils and platelets. CD23 is the low-affinity receptor for immunoglobulin IgE 
and plays important roles in the regulation of IgE responses. CD23 can be cleaved 
from cell surfaces to yield a range of soluble CD23 (sCD23) proteins that have 
pleiotropic cytokine-like activities. The regions of CD23 responsible for interaction 
with many of its known ligands, including IgE, CD21, major histocompatibility 
complex (MHC) class II and integrins, have been identified and help to explain the 
structure–function relationships within the CD23protein.Translational studies of 
CD23 highlight its credibility as a target for therapeutic intervention strategies and 
illustrate its involvement in mediating therapeutic effects of antibodies directed at 
other targets (Acharya et al., 2010). 
 
The involvement of CD23 in the IgE system, immune regulation and as a cytokine 
and signalling receptor has made it an obvious target for therapeutic intervention. 
Soluble CD23 levels are elevated in a range of disease conditions with an 
autoimmune or inflammatory component, including in patients with Sjögren’s 
syndrome, in systemic lupus erythematosus (SLE) patients, and in rheumatoid 
arthritis cases. In rheumatoid arthritis there is a striking elevation in sCD23 in plasma 
and synovial fluid, and particularly in the latter during erosive disease flares (Bansal 
et al., 1992 and Massa et al., 1998). In these scenarios, the elevated sCD23could 
arise either from polyclonal activation of B cells or by activation of monocytes, and in 
all cases it is equally unclear how sCD23 might contribute to the pathology of the 
disease. However, as sCD23 binds numerous receptors on monocytes (αMβ2, αXβ2, 
αvβ3, αvβ5) to promote the release of proinflammatory cytokines [Figure 1.6(2)], it is 
possible that sCD23 itself behaves as a proinflammatory cytokine. Soluble CD23, 
released from activated B cells at the inflamed site, could act in a juxtacrine manner 
to promote cytokine release by monocytes, while sCD23 released by macrophages 
could then act in an autocrine manner to promote further and sustained cytokine 
release, thus exacerbating the response. Perturbing this mode of sCD23 activity 
would be a potentially useful adjunct to notably successful anti-tumour necrosis 
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factor (TNF)-α therapies such as etanercept and infliximab (Huissoon et al., 2000, 
Ribbens et al., 2000 and Taylor et al., 2009). 
 
CD23 has multiple ligands, including IgE, CD21 and members of two families of 
integrins. The principal ligand is IgE, which is bound by both membrane-bound and 
soluble trimeric CD23 species. The site recognized by CD23resides in the Cε3 
domain of IgE and CD23 sterically hinders IgE binding to FcεRI. Binding of IgE to 
CD23is carbohydrate-independent i.e. does not require any lectin-like activity of the 
head domain. The next best characterized ligand for CD23 is CD21. The interaction 
with CD21 depends on short consensus repeats in CD21 and occurs when the 
proteins are freely soluble in solution (sCD21–sCD23 complexes are readily 
detected in plasma), or are membrane proteins. In the case of membrane proteins, 
activation of human B cells promotes homotypic adhesion, and the cell clusters are 
disrupted byanti-CD21 or anti-CD23 antibodies, indicating that these two membrane 
proteins can interact functionally intrans. The interaction of CD23 with CD21involves 
both carbohydrate-dependent and independent interactions, and the interaction of 
derCD23 withCD21 is approximately micromolar, KD ~ 8.7 x10-7M (Aubry et al., 
1992/1994 and Hibbert et al., 2005). As CD21 is expressed by B cells, follicular 
dendritic cells (FDCs), activated T cells and basophils, adhesion pairing between 
these two molecules may have important consequences for allergies (Gould and 
Sutton, 1998).CD23 can also interact in cis and trans with major histocompatibility 
complex (MHC) class II proteins, in a carbohydrate-independent manner, using 
structures in theCD23 protein that are located in the stalk region of the molecule. 
This interaction is believed to facilitate antigen processing and presentation by 
antigen–IgE complexes captured by CD23 (Kijimoto-Ochiai et al., 2000 and Flores-
Romo et al., 1990). 
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Figure 1.6: Human CD23 and its interacting molecules (1) Membrane-bound and soluble 
CD23 can bind IgE and thereby play a role in antigen focusing and presentation. (2) CD23 
can activate monocytes/macrophages by binding to the β2 integrins CD11b/CD18 or 
CD11c/CD18, playing a role in inflammatory diseases. (3) CD23 can interact with CD21 
(complement receptor 2 and Epstein-Barr virus receptor) on B cells and preferentially 
upregulate IgE production (Bonnefoy et al., 1996). 
 
CD23 binds IgE (an antibody isotype involved in the allergic response) in an unusual, 
non-lectin-like manner which requires calcium but not carbohydrates (Wurzburg et 
al., 2006). The interaction between CD23 and IgE is accountable for protective 
functions such as phagocytic clearance of antigens and cellular cytotoxicity, although 
it is also associated with delayed allergic reactions (Beavil et al., 1992). CD23 
engages in both the up and down regulation of IgE production, thereby establishing a 
two-way switch in IgE homeostasis. CD23 binds IgE with both high and low affinity. 
However, the increase in surface CD23 does not lead to an increase in IgE binding. This 
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dual affinity was explained by Gould et al. (2003) to be related to the oligomerization 
of CD23. According to this model, low affinity binding occurs when one molecule of 
IgE is bound to one CD23 molecule, and high affinity binding occurs when a 
molecule of IgE is bound by multiple CD23 receptors at the same time. These 
opposing activities of CD23 in IgE regulation are considered to be characteristics of 
the soluble and membrane forms of CD23 where soluble CD23 enhances IgE 
synthesis upon binding to CD21 and when IgE binds to membrane CD23, further IgE 
synthesis is suppressed (Hibbert et al., 2005). 
 
Characterization of the CD23-IgE interaction has primarily been achieved through 
the use of 16 kDa CD23 and IgE-Fc (Chretien et al., 1988, Ghaderi and Stanworth, 
1993; Dhaliwal et al., 2012; Borthakur et al., 2012). The majority of these studies 
revealed that the lectin domain of CD23 binds to IgE within the Cε3 domains. 
However, the crystal structure of 16 kDa CD23–Fcε3-4 revealed that the lectin 
domain of CD23 also makes contact with the Cε3-Cε4 linker region and the Cε4 
domains of IgE-Fc (Dhaliwal et al., 2012). Furthermore, the crystal structure 
confirmed that the stoichiometry of the sCD23-IgE-Fc interaction is 2:1, a finding 
previously suggested by Shi et al. (1997). The affinity of monomeric CD23 for IgE-Fc 
has been found to be quite low (Ka ~106-107 M-1), while the affinity of trimeric CD23 
for IgE-Fc is much higher (Ka ~108–109 M–1) (Gould and Sutton, 2008). 
 
Previously, Bowles et al. (2011) showed that the C-terminal tail region of CD23 can 
also play a role in the CD23-IgE interaction. They analysed the interaction of native 
IgE with 16, 25 and 37 kDa CD23 using surface plasmon resonance (SPR) 
spectroscopy and showed a positive relationship between stalk length and affinity. 
The affinities observed were very similar though, which may indicate that the stalk 
region only plays a minor role in the CD23-IgE interaction.  
 
The functional significance of CD23 binding to CD11b/c was previously 
demonstrated by triggering CD11b and CD11c on monocytes with either 
recombinant CD23 or anti-CD11b and anti-CD11c monoclonal antibodies (mAbs), 
which caused a marked increase in nitrite (NO2-) oxidative products(H2O2) and 
proinflammatory cytokines. Furthermore, CD23 elicits an increase in the production 
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of interleukin 1α (IL-1α), interleukin1β (IL-1β), interferon γ (IFN-γ), IL-6 and tumour 
necrosis factor α (TNF-α). These CD23-mediated activities are inhibited by Fab 
fragments of mAbs to CD11b, CD11c and CD23. Together, these results suggested 
that CD11b and CD11c are functional receptors for CD23, and that CD23 is a 
proinflammatory mediator (Bonnefoy et al., 1996). 
 
1.4.3 Interaction between CD23 and β2 Integrins 
 
CD23 has been found to interact with four members of the integrin superfamily. This 
includes αMβ2 (CD11b/CD18 or CR3), αXβ2 (CD11c/CD18 or CR4), αVβ3 and αVβ5 
(Hibbert et al., 2005; Edkins et al., 2012).  
 
Soluble CD23 inhibits apoptosis in pre-B cell lines through an interaction with the 
αvβ5 integrin. In association with interleukin-1α, sCD23 promotes differentiation of 
monocytes and early thymocyte precursors and, via binding to the αMβ2 (CD11b- 
CD18), αXβ2 (CD11c-CD18), and αvβ3integrins stimulates tumour necrosis factor-α 
and interleukin-1α production by monocytes (Borland et al., 2007).  
 
On eosinophils and platelets, CD23 binds IgE-coated particles causing their 
phagocytosis and the release of cytokines. In this role, CD23 acts in conjunction with 
CD11b/CD18 for both adherence and cytotoxicity. This is because the interaction 
between CD23 and CD11b/CD18 or CD11c/CD18 causes stimulation of IL-1β, IL-6 
and TNF-α release, macrophage activation and increased production of nitrate-
oxidative products (Lecoanet-Henchoz et al., 1995; Paul-Eugene et al., 1992).  
 
The two leukocyte specific integrins, αMβ2 and αXβ2, were first shown to interact with 
CD23 by Lecoanet-Henchoz et al. (1995). They showed that it was only the αM 
andαX (CD11b/c) chains that directly interacted with CD23. Subsequently, the α-I 
domain was shown to be responsible for the interaction with the lectin domain of 
CD23 (Daniels, 2010). 
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Converse to the αMβ2 and αXβ2, the αV chains of αVβ3 and αVβ5 integrins lack the α-I 
domain. Integrins that lack the α-I domain have been shown to bind to ligands with 
the β-I domain in CD18 (Gahmberg et al., 2009).However, β-I domain dependent 
interaction of αVβ3 and αVβ5 with CD23 remains to be determined. Nevertheless, 
Borland et al. (2007) have performed far-western analysis that implicates the β3 and 
β5 chains in CD23 binding, specifically using CD23 derived arginine-lysine-cysteine 
(RKC) containing peptides. Edkins et al. (2012) investigated the binding site on 
CD23 responsible for interaction withαVβ3 and αVβ5. They found that peptides 
containing the RKC motif of CD23 (residues 172 – 174) were able to bind both αVβ3 
and αVβ5. RKC-containing peptides derived from CD23 show dose-dependent, 
biphasic binding profiles to both αVβ3 and αVβ5 that are cation-independent but 
sensitive to high chloride ion concentrations. Substitution of one basic residue in the 
RKC motif with alanine reduces, but does not abolish, integrin binding or the ability of 
peptides to stimulate pre-B cell growth or cytokine release by monocytes. 
Substitution of both basic residues abolishes both integrin binding and biological 
activity of CD23-derived peptides. These features indicate that binding of RKC-
containing peptides to αV integrins has clearly distinct characteristics to those for 
binding of RGD-containing ligands. 
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2 AIM OF RESEARCH 
 
 
2.1 Problem Identification 
 
Both CD23 and the β2 integrins are involved in important immunological responses. 
CD23 is involved in growth and differentiation of T and B cells, apoptotic rescue of B 
cells, cellular adhesion, IgE regulation, release of inflammatory mediators and 
phagocytosis. The binding characteristics of integrins are of great clinical interest 
due to their involvement in defective embryogenesis, blood coagulation, 
osteoporosis, acute renal failure, retinopathy cancer and inflammation.  
 
On monocytes, sCD23 binds the β2 integrins, CD11b/CD18 (αMβ2) and CD11c/CD18 
(αXβ2), and to the αVβ3 vitronectin receptor (VnR) isoform promoting pro-
inflammatory cytokine synthesis. However, the protein domains responsible for the 
CD23-integrin interactions are not yet well defined (Arnaout, 2009). The mechanism 
of CD23 binding β2 integrins requires further elucidation. This information could then 
assist in the understanding of allergic and inflammatory disease and therefore the 
development of more specific interventions for allergic and inflammatory conditions. 
 
In view of the fact that it was determined by Diamond et al. (1993) and Nham (1999) 
that the I-domain is indeed involved in β2 integrin ligand interactions and since it was 
determined by Borland et al. (2007) that the RKC motif on sCD23 is one of the 
principal interaction surfaces between sCD23 and the β5 integrin family, it would be 
useful to probe the interaction surface between the I-domain of CD11b and the RKC 
motif of sCD23. A site-directed double mutant prepared by Pereira, (2012), where 
RKC was mutated to AAC, was investigated in order to verify the importance of this 
motif in the CD23-CD11 interaction. 
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It has recently been found that binding of CD23 to CD11 is partly due to the αI 
domain (Daniels, 2010). CD23 may be acting as a C-type lectin in its interaction with 
CD11b and CD11c. EDTA decreases CD23 binding to monocytes by chelation of 
Ca2+, which is necessary in CD23 binding, or by chelation of the divalent cations, 
which are necessary for the binding of ligands to the β2 integrins (Altieri, 1991). The 
role of calcium as well as the presence of the ADMIDAS domain in the β2 subunit 
may indicate the involvement of CD18 in β2 integrin binding to CD23.  
 
In 2009, Gahmberg and colleagues showed that in integrins lacking the α chain I-
domain, the β I-like domain is the primary ligand binding site. Integrin conformation is 
dependent on the β chain, and an allosteric regulation of the α chain I-domain by the 
β chain I-like domain is essential for ligand binding (Gahmberg et al., 2009).  
 
Naturally occurring mutations identified in LAD-1 patients provide useful insights into 
the possible functions of residues and domains of the β2 integrins. Two such 
mutations, S116P and D209H, exemplify the importance of the MIDAS and SyMBS, 
respectively, of the β2 I-like domain in ligand binding function (Cheng et al., 2007). 
 
Ligand binding studies for the β2 integrins are typically carried out with complete 
integrins, expressed in mammalian cell lines. The use of a recombinant bacterial 
expression system for specific domains is simpler and may provide more 
comprehensive knowledge of ligand binding interactions within the β2 integrins.  
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2.2 Research Objectives 
 
In order to further elucidate the interaction between CD23 and β2 integrins 
(CD11b/CD18) the following objectives were established:  
 
 Expression and purification of CD11b I-domain as a GST-fusion protein using 
Escherichia coli. 
 
 Cloning, synthesis and expression of CD18 I-Like domain.CD11b I-domain 
has previously been expressed as a GST-fusion protein (Daniels, 2010) and 
consequently led to comparable expression of CD18 I-like domain as a GST-
fusion protein. 
 
 Preparation of two site-directed mutants of CD18 I-Like domain in order to 
study the function of the serine residue involved in the S116P mutation. The 
serine was mutated to proline, as in LAD patients, as well as alanine, a non-
polar alternative, in order to contrast and compare binding characteristics. 
 
 Expression, refolding and purification of sCD23, and a double mutatedsCD23 
(RKΔAA) from E. coli. This was performed according to the method described 
by Daniels et al. (2005).  
 
 Investigation of the CD23-CD11b I-like domain interaction through surface 
plasmon resonance spectroscopy. 
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3 PREPARATION AND PURIFICATION OF EXPRESSION 
VECTORS 
 
 
Many proteins are expressed at low levels in vivo, but in order to study their 
interaction in vitro, high levels of recombinant proteins may be produced via 
expression in a host system. 
 
3.1 Introduction 
In order to study the specific interactions between CD23 and the β2 integrins, CD11b 
I-domain and CD18 I-like domain were expressed as recombinant proteins using E. 
coli as a host. The production of genetically engineered proteins requires the cloning 
of the desired fragment of DNA into a vector that will express the protein. The vector 
is then used to transform the host cell and expression is controlled by means of an 
inducer.  
 
To express CD23, the pET vector system was used. To express the CD11b I-
domain, the pGEX vector system was used and therefore, in order to express the 
CD18 I-like domain, a similar GST fusion system (pET42b) was selected based on 
the degree of homology between the domains.  
 
3.1.1 Bioinformatic Analyses 
To express novel recombinant proteins, the cloning procedure must be carefully 
designed and considered. Bioinformatics has become integral in the initial stages of 
designing a cloning experiment. Some common bioinformatic tools include a 
searchable database of genes and proteins, gene homology, BLAST, protein 
docking and modelling and a wide variety of protein characterization, identification 
and prediction analyses. These tools are easily accessible from a few helpful 
websites and online databases (Table 1.1).  
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Table 1.1: Various websites with their relevant bioinformatic tools available online.  
Website Example Of Tools Available 
http://www.ncbi.nlm.nih.gov GenBank, BLAST, Conserved Domains, 
Structure modelling 
http://www.expasy.org/genomics sequence alignment 
similarity search 
characterisation/annotation 
http://www.expasy.org/Proteomics protein sequences and identification 
mass spectrometry and 2-D data 
protein characterisation and function 
families, patterns and profiles 
post-translational modification 
protein structure 
protein-protein interaction 
similarity search/alignment 
 
Once the gene of interest has been located using NCBI’s GenBank, the DNA coding 
sequence can be analysed using their online conserved domains and structural 
analysis tools. The DNA coding sequence can then be digitally translated to the 
amino acid sequence, using ExPASy, and analysed using ExPASy’s structure and 
function tools. An important consideration when expressing eukaryotic proteins in a 
prokaryotic system is the post-translation modification differences and rare-codon 
usage. 
 
3.1.2 Rare Codons 
 
Most amino acids are encoded by more than one codon, and each organism carries 
its own bias in the usage of the 61 available amino acid codons. In each cell, the 
tRNA population closely reflects the codon bias of the mRNA population. When the 
mRNA of heterologous target genes is over expressed in E. coli, differences in 
codon usage can impede translation due to the demand for one or more tRNAs that 
may be rare or lacking in the population. Insufficient tRNA pools can lead to 
translational stalling, premature translation termination, translation frameshifting and 
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amino acid misincorporation (Brinkmann et al., 1989; Seidel et al., 1992; Kane, 1995; 
Kurland and Gallant, 1996). This issue can be overcome by using a host strain 
(RosettaTM) which is able to supply the rare tRNAs encoded on a plasmid, or by 
synthesizing the codon optimised coding DNA.   
 
The Rosetta™ strains are designed to enhance the expression of eukaryotic proteins 
that contain codons rarely used in E. coli (Brinkmann et al., 1989; Seidel et al., 1992; 
Kane, 1995; Kurland and Gallant, 1996). Expression of such proteins can be 
dramatically increased when the level of rare tRNA is increased within the host 
(Brinkmann et al., 1989; Seidel et al., 1992; Rosenberg et al., 1993; Del Tito et al., 
1995). Rosetta strains supply tRNAs for the codons AUA, AGG, AGA, CUA, CCC 
and GGA on a compatible chloramphenicol resistant plasmid. These strains provide 
enhanced expression of target genes otherwise limited by the codon usage of E. coli 
(Novy et al., 2001). 
 
Alternatively, GenScript's OptimumGene™ Gene Design system is a proprietary 
gene optimization technology that can alter recombinant gene sequences in order to 
achieve the highest possible levels of productivity in any given expression system. 
The OptimumGene™ algorithm takes into consideration a variety of critical factors 
involved in different stages of protein expression, such as codon adaptability, mRNA 
structure, and various cis-elements in transcription and translation. 
 
GenScripts OptimumGene algorithm assesses codon adaptability which is based on 
the codon usage bias of a specific organism. Codon usage bias refers to differences 
in synonymous codons in coding DNA, and therefore tRNA populations, within a 
single organism when compared to other organisms. Within E. coli and other 
species, a clear codon bias exists among the 61 amino acid codons found within the 
population of mRNA molecules, and the level of cognate tRNA appears directly 
proportional to the frequency of codon usage. Therefore, recombinant genes that 
contain codons which are rare in E. coli may be inefficiently expressed by this 
organism (Kane, 1995). In addition, mRNA half-life is enhanced by optimising GC 
content and removing unfavourable GC peaks, as well as removing stem-loop 
structures which impact ribosomal binding and stability of mRNA (Genscript, 2013).  
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3.1.3 pET System 
 
According to Novagen, the pET System is the most powerful system yet developed 
for the cloning and expression of recombinant proteins in E. coli. Target genes are 
cloned in pET plasmids and are under the control of strong bacteriophage T7 
transcription and translation signals; expression is induced by providing a source of 
T7 RNA polymerase in the host cell. T7 RNA polymerase is so selective and active 
that, when fully induced, almost all of the cell’s resources are converted to target 
gene expression. The desired product can comprise more than 50% of the total cell 
protein a few hours after induction. Although this system is extremely powerful, it is 
also possible to adjust expression levels simply by adjusting the concentration of the 
inducer isopropyl-β-D-thiogalactopyranoside (IPTG). Decreasing the expression level 
may enhance the soluble yield of some target proteins.  
 
Another important benefit of this system is its ability to maintain target genes 
transcriptionally silent in the uninduced state. Target genes are initially cloned using 
hosts that do not contain the T7 RNA polymerase gene, thus eliminating plasmid 
instability due to the production of proteins which may be toxic to the host cell. 
Clones are then transferred to an expression host containing a chromosomal copy of 
the T7 RNA polymerase gene under lacUV5 control. Expression is then induced by 
the addition of IPTG to the bacterial culture.  
 
There are two categories of pET vectors; transcription and translation vectors. 
Transcription vectors were designed to express target genes carrying their own 
prokaryotic ribosome binding site and AUG start codon. Translation vectors are 
distinguished by the addition of a letter suffix following the name, which indicates the 
reading frame relative to the BamH1 cloning recognition sequence GGATCC. 
Vectors having an ‘a’ suffix express from the GGA triplet while those with a ‘b’ 
express from the GAT triplet. All pET translation vectors possess translation stop 
codons in all three reading frames following the MCS, as well as a downstream T7 
transcription terminator. pET vectors also carry an antibiotic resistance gene to 
assist with positive identification of transformed host cells (Novagen User Manual 
TB055, 2013). 
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When choosing a vector system for expression of recombinant proteins, there are 
various considerations that must be taken into account; the application intended for 
the expressed protein, specific information known about the expressed protein and 
cloning strategy. An important consideration, in this case, was solubility of the 
recombinant protein. In many applications, it is desirable to express proteins in their 
soluble, active form. In most cases, solubility is not an all-or-none phenomenon; the 
vector, host, and culture conditions can be used to increase or decrease the 
proportion of soluble and insoluble forms obtained.  
 
The choice of vector and expression host can significantly increase the activity and 
amount of target protein present in the soluble fraction. A vector can enhance 
solubility and/or folding in one of three ways: 1) provide for fusion to a polypeptide 
that itself is highly soluble [e.g. glutathione-S-transferase (GST), thioredoxin (Trx), N 
utilization substance A (NusA),maltose binding protein (MBP)], 2) provide for fusion 
to an enzyme that catalyzes disulfide bond formation (e.g. thioredoxin, DsbA, DsbC), 
or 3) provide a signal sequence for translocation into the periplasmic space (MBP). 
 
3.1.4 The GST-Gene Fusion system 
 
The glutathione S-transferase (GST) Gene Fusion System is a versatile system for 
the expression, purification and detection of fusion proteins produced in E. coli. The 
system is based on inducible, high-level expression of genes or gene fragments as 
fusions with Schistosoma japonicum GST. Expression in E. coli yields fusion proteins 
with a GST moiety at the N-terminus which accumulates in the cell cytoplasm.  
 
GST occurs naturally as a Mr 26 000 protein that can be expressed in E. coli with full 
enzymatic activity. Fusion proteins also demonstrate GST enzymatic activity and can 
undergo dimerization similar to that observed in nature. GST fusion proteins are 
purified from bacterial lysates by affinity chromatography using immobilized 
glutathione. Fusion proteins are eluted under mild, non-denaturing conditions using 
reduced glutathione. GST can be cleaved from the protein using a site-specific 
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protease (usually factor Xa or thrombin) whose recognition site is located directly 
upstream of the multiple cloning site.  
 
GST fusion proteins are constructed by inserting a gene or gene fragment into the 
multiple cloning site (MCS) of either a pGEX or pET42 vector. All pGEX vectors are 
engineered with an internal lac Iq gene and expression is controlled by the tac 
promoter, which is induced by the lactose analog, IPTG. The lac Iq gene product is a 
repressor protein which binds to the operator region of the tac promoter thereby 
preventing expression until induction by IPTG and maintaining tight control over 
expression of the insert.  
 
 
3.2 Materials 
 
pET-28 vectors containing the insert sequences of 25kDa CD23 and mutant CD23 
were donations from Brodie Daniels and Melanie Pereira (NMMU, South 
Africa).pGEXCD11bI vector containing the insert sequence for CD11b I-domain was 
kindly donated by Dr. Sang-Uk Nham (Kangwon National University, Korea). Plasmid 
8638 Integrin beta 2 – mYFP containing the insert sequence of CD18 was obtained 
from Addgene (USA). pET42b vector was purchased from Novagen (Germany). E. 
coli DH5α cloning strain was obtained from Invitrogen. T4 DNA ligase was obtained 
from New England Biolabs (USA) and restriction enzymes, HindIII and XhoI, and 1kb 
GeneRuler were obtained from Fermentas (Lithuania). KapaTaq ReadyMix was 
purchased from KAPABiosystems (South Africa). QuickChange II XL Site-Directed 
Mutagenesis Kit was purchased from Stratagene (USA). All other reagents used 
were of the highest available quality. 
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3.3 Methods 
 
3.3.1 Cloning and Synthesis of the CD18 β I-Like Domain Expression Vector 
 
The coding region for human CD18 was defined using NCBI’s Genbank (Accession: 
NM_000202.2, Gene ID 3689) and confirmed using BLAST, and correlated to the 
integrin beta2 gene (ITGB2). The β I-Like domain was defined using UniProtKB 
(P05107). 
 
A polymerase chain reaction (PCR) directional cloning technique was employed to 
amplify the coding region for human CD18 β I-Like domain. This was followed by 
restriction digestion, ligation into a pET42b GST-fusion expression vector to create 
the vector shown in Figure 3.1, and transformation of the E. coli host cell. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Vector map for CD18 I-like domain expression vector. GST gene fusion proteins 
produced via expression using a pET42b vector can be purified using affinity 
chromatography under mild conditions suited to maintaining solubility of the recombinant 
protein. 
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Bioinformatic analyses revealed the necessity for synthesizing the entire coding 
region in order to codon optimise the gene for expression in a prokaryotic system. 
This was performed by GenScript (USA) and the synthesized sequence was named 
CD18 ILDopt (for optimised). 
 
 
3.3.1.1 Primer design 
 
Primers were designed for the PCR amplification of the CD18 β I-Like domain (ILD) 
coding region (Table 3.1). The forward and reverse primers were designed with 
restriction sites for the endonucleases HindIII and XhoI, respectively. These were 
used for digestion of the amplified CD18 β ILD DNA and the pET42b plasmid to 
allow for directional cloning into the expression vector.   
 
 
 
Table 3.1: Primers used for the PCR amplification of CD18 β I-Like domain coding 
region. 
Primer Name Sequence 
Forward KSCD18ILDf 5’ - TTG AAG CTT TAC CTG CG – 3’ 
Reverse KSCD18ILDr 5’ - TGG TCT CGA GTT TAT TGT AAG C – 3’ 
 
 
  
3.3.1.2 PCR Amplification of CD18 β I-Like Domain 
 
Polymerase chain reaction amplification was used to generate large quantities of the 
DNA encoding CD18 ILD. The PCR reaction was performed according to Sambrook 
et al., (1989). The template used for amplification was Plasmid 8638 Integrin beta 2 
– mYFP and the reaction mix is shown in Table 3.2. 
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Cycle 1 (1X) Step 1: 95°C for 5min 
 
Cycle 2 (25X) Step 1: 95°C for 45s 
  Step 2: 55°C for 30s 
  Step 3: 72°C for 60s 
 
Cycle 3 (1X) Step 1: 72°C for 10min 
Table 3.2: PCR reaction mix used in all cases. 
Reagent Volume per tube (μL) 
KapaTaq ReadyMix 2X 10 
Primer (Forward) 0.75 
Primer (Reverse) 0.75 
Template DNA ~0.5 (~50ng) 
H2O Up to 20μL 
Total Volume 20μL 
 
 
A temperature gradient PCR was performed in order to determine the optimum 
temperature for the annealing of the primers. The temperature range used was 50°C 
to 65°C. After determination of the optimum temperature, this temperature was used 
to amplify the coding region for CD18 ILD. The PCR reaction was carried out with 
the parameters shown in Figure3.2. 
 
 
 
Figure 3.2: Standard thermocycling protocol for amplification of target DNA, showing the 
temperature and duration of each cycle, as a schematic representation of thermo 
cycles as well as the reaction conditions of PCR amplification. 
 
The amplified CD18 ILD DNA fragment resulting from the PCR reaction was verified 
using agarose gel electrophoresis (AGE). 
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3.3.1.3 Agarose Gel Electrophoresis 
 
AGE was used as the chief analytical and preparative separation technique of DNA. 
All gels were prepared such that they contained 1% agarose and 0.5 μg/mL of 
ethidium bromide in Tris-acetate-EDTA (TAE) buffer (40 mM Tris, 20 mM acetate, 1 
mM EDTA, pH 8).Electrophoretic separation of DNA, mixed with loading dye [0.4% 
orange G, 0.03% bromophenol blue, 0.03% xylene cyanol FF, 30 % glycerol, 10 mM 
Tris-HCl (pH 7.5) and 50 mM EDTA (pH 8.0)], as well as a size marker (GenerulerTM 
1kb DNA ladder, Fermentas) was achieved using 90 V and 400 mA for 45 min; with 
TAE as the electrophoresis buffer (Sambrook et al., 1989). Gels were visualised with 
transilluminated and reflected UV light and digital photographs were taken with an 
AlphaImagerTM 3400.  
 
3.3.1.4 Quantification of DNA 
 
DNA concentration was determined using the NanoDrop 2000c. Special attention 
was given to A260/A280 and A260/A230 ratios; indicating contamination by proteins 
and organic compounds, respectively. According to the NanoDrop 2000c (Thermo 
Fischer Scientific) user manual A260/A280 and A260/A230 values should be higher 
than 1.8 for ‘pure’ DNA.  
 
 
3.3.1.5 Restriction Digestion and Ligation 
 
Restriction digestion was used for analytical and preparative purposes. Restriction 
enzymes were used according to the manufacturer’s instructions.  
 
Analytical reactions were carried out in 25 μL volumes, while preparative reactions 
were carried out in 50μL volumes. In all cases restriction digestion was carried out at 
37°C for 4 hours. Furthermore, restriction enzymes never comprised more than 10% 
of the total reaction mixture in order to limit the occurrence of star activity due to 
excessive levels of glycerol. The reaction mixture for amplicon and vector/plasmid 
digestion is shown in Table 3.3 and 3.4, respectively. 
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Table 3.3: Restriction endonuclease digestion of CD18 ILD amplicon. 
Reagent Volume per tube (μL) 
PCR Amplicon (CD18 ILD) 39 
Buffer R (10X) 5 
XhoI 2.5 
HindIII 2.5 
ddH2O 1 
Total volume 50 
 
Table 3.4: Restriction endonuclease digestion of pET42b vector. 
Reagent Volume per tube (μL) 
Vector pET42b 25 
Buffer R (10X) 5 
XhoI 2.5 
HindIII 2.5 
ddH2O 15 
Total volume 50 
 
The digested DNA (amplicon and vector pET42b) was electrophoresed on agarose 
as described in Section 3.3.1.3 and the required fragments were extracted and 
purified using QIAquick Gel Extraction Kit. The bind-wash-elute procedure, exploiting 
the ability of silica membranes to bind/elute DNA in the presence of high/low salt 
conditions, ensured that rapid and convenient purification of DNA from agarose was 
achieved. 
 
The ligation reactions were performed on ice, overnight, using T4 DNA ligase in a 
ligase specific buffer. The molar ratios of vector to insert used were 1:1, 1:3 and 3:1.  
 
3.3.1.6 Transformation of chemically competent E.coli 
 
Chemically competent DH5α E. coli bacteria were used as the cloning strain. In 
addition to supporting blue/white screening, recA1 and endA1 mutations in DH5α 
cells increase insert stability and improve the quality of plasmid DNA prepared from 
minipreps.  
  33 
 
Chemically competent cells [E. coli DH5α and BL21 (DE3)]were prepared using the 
calcium chloride method described by Sambrook et al., (1989) where 1ml of 
overnight culture was used to inoculate 1L double strength Yeast Tryptone broth 
(16g tryptone, 10g yeast extract, 5g NaCl, pH 7.0) and incubated at 37°C. Cell 
growth was monitored at 600nm until an absorbance value of 0.3-0.4 was obtained. 
The cells were then transferred to two separate 500ml centrifuge bottles and kept on 
ice for 20 minutes. Cells were collected via centrifugation at 3000xg for 10 minutes 
(4°C) and resuspended in 2x 7ml chilled CM solution (50mM CaCl2, 50mM MgCl2 
and 10% w/v glycerol). The solution was incubated on ice for 30 minutes, followed by 
centrifugation as above. Pelleted cells were resuspended in 3.6ml chilled CM 
solution and incubated on ice again for 30 minutes. To ensure cryopreservation of 
competent cells, 250μl dimethyl sulfoxide (DMSO) was added stepwise over 30 
minutes on ice. The cells were transferred to Eppendorf tubes in 200μl aliquots, snap 
frozen with liquid nitrogen and stored at -80°C. 
 
E.coli DH5α competent cells were transformed with DNA by gently thawing 200μl of 
competent cells on ice and adding 5μl of ligation mix before gently swirling them and 
incubating them on ice for fifteen minutes. The mixture was incubated at 42°C for 
thirty seconds before incubating on ice for two minutes. Cells were incubated at 37°C 
with 100 μL of Luria Bertani (10 g Tryptone, 10 g NaCl, 5 g Yeast extract) broth for 
one hour. The transformed cells (50μl) were plated onto LB agar plates (LB broth 
with 15 g/L bacteriological agar) containing kanamycin (15μg/ml) and incubated 
overnight at 37°C. 
 
The resulting colonies were restreaked and used to inoculate 10ml LB broth as 
overnight cultures. Vectors were isolated using a NucleoSpin® Plasmid kit 
(Macherey-Nagel, Germany) following manufacturer’s instructions.  
 
3.3.1.7 Confirmation of clones 
 
Three methods were used to confirm the clones; colony PCR, restriction digestion 
and DNA sequencing. 
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Colony PCR was performed as described in section 3.3.1.2 with the exception of the 
template DNA. In the case of colony PCR, a colony from an agar plate is added 
directly to the reaction mix instead of purified template DNA. The denaturation step is 
sufficient to lyse the cells and release the vector DNA as template for the primers 
present in the reaction mix. This is a quick and easy method to confirm the presence 
of the inserted amplicon within the new vector 
 
The overnight cultures were used to isolate vector DNA using a NucleoSpin® 
Plasmid kit (Macherey-Nagel, Germany) which was then used as template DNA for 
restriction digestion (section 3.3.1.5). Following agarose gel electrophoresis, the 
presence of the correct sized bands indicates a successful cloning procedure.  
 
Purified recombinant vectors were sent to the Central Analytical Facility (CAF) at 
Stellenbosch University where DNA was sequenced using vector specific primers to 
verify the integrity of the CD18 ILD coding DNA. 
 
 
3.3.1.8 Site-Directed Mutagenesis 
 
Two site-directed mutants of the CD18 ILD were prepared in order to study the 
function of the serine 116 residue. The serine was mutated to proline, as occurs in 
LAD patients, as well as alanine, a non-polar alternative, in order to contrast and 
compare.   
 
The basic procedure requires the synthesis of a short DNA primer set which is 
complementary to the template DNA around the site where the mutation is to be 
introduced. The mutation may be an insertion, deletion or single base change. This 
synthetic primer is complementary to the template DNA flanking the base change so 
it can hybridize with the DNA containing the gene of interest. The single-stranded 
primer is then extended using a DNA polymerase, which copies the rest of the gene. 
The resulting gene, containing the mutated site, is then introduced into a host cell as 
a vector and cloned. Finally, mutants are selected.  
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Site-directed mutagenesis was performed using the QuickChange II XL Site-Directed 
Mutagenesis Kit, (Stratagene, catalogue number 200521), according to manufacturer 
instructions. According to Stratagene, this kit delivers mutant plasmids without losses 
in mutagenesis efficiency or accuracy and has been optimized for mutagenesis of 
plasmids of up to 14 kb. It allows for rapid, efficient and accurate mutagenesis of 
small and large plasmids with a single kit. 
 
 
 
 
Figure 3.3: Overview of the QuikChange II XL site-directed mutagenesis method (Stratagene 
manual). 
 
 
Mutant strands were synthesized by denaturing the CD18 ILD expression plasmid 
(shown in figure 3.1) and annealing mutagenic primers containing the desired 
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mutation. In this case our focus was on the DLSYS motif known as the MIDAS. The 
mutation in LAD patients is S116P, serine to proline, so a mutation from DLSYS to 
DLSYP. We also chose to mutate the serine to alanine in order to determine 
functionality when a polar amino acid, known to be involved in binding, is mutated to 
a non-polar amino acid.  
 
The primers designed for site directed mutagenesis are shown in Table 3.5, the 
reaction mix shown in Table 3.6 and the cycling parameters shown in Table 3.7.  
 
Table 3.5: Primers used for Site-Directed Mutagenesis of CD18 ILD serine to proline or 
alanine with the mutated nucleotide shown in bold and underlined. 
Target Name* Sequence (5’ – 3’) 
Alanine 
SDMCD18S138Af TAT CTG ATG GAC CTC TCC TAC CCC ATG CTT GAT GAC CTC AGG 
SDMCD18S138Ar CCT GAG GTC ATC AAG CAT GGG GTA GGA GAG GTC CAT CAG ATA 
Proline 
SDMCD18S138Pf TAT CTG ATG GAC CTC TCC TAC GCC ATG CTT GAT GAC CTC AGG 
SDMCD18S138Pr CCT GAG GTC ATC AAG CAT GGC GTA GGA GAG GTC CAT CAG ATA 
Alanine 
SDMCD18optAf CTG ATG GAT CTG AGC TAT GCT ATG CTG GAT GAC CTG 
SDMCD18optAr CAG GTC ATC CAG CAT AGC ATA GCT CAG ATC CAT CAG 
Proline 
SDMCD18optPf CTG ATG GAT CTG AGC TAT CCT ATG CTG GAT GAC CTG 
SDMCD18optPr CAG GTC ATC CAG CAT AGG ATA GCT CAG ATC CAT CAG 
*Primer sets designed to mutate serine to proline or alanine for both the wild-type CD18ILD and a 
codon optimized CD18ILDopt.  
 
 
Table 3.6: PCR reaction mix used for Site-Directed Mutagenesis 
Reagent Volume (μL) per tube 
Reaction Buffer (10X) 5 
DNA Template 0.5 
Primer (Forward) 2.5 
Primer (Reverse) 2.5 
DNTP 1 
Quick Solution 3 
ddH2O 35.5 
Pfu polymerase 1 
Total Volume 51 
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Table 3.7: Cycling parameters used for the QuikChange II XL method of Site-Directed 
Mutagenesis (Stratagene Manual) 
Segment Cycles Temperature Time 
1 1 95°C 1 Minute 
2 18 
95°C 50 Seconds 
60°C 50 Seconds 
68°C 7 Minutes 
3 1 68°C 7 Minutes 
 
The oligonucleotide primers, each complementary to opposite strands of the vector, 
are extended during temperature cycling by Pfu Ultra HF DNA polymerase, without 
primer displacement. Extension of the oligonucleotide primers generates a mutated 
plasmid containing staggered nicks. Following temperature cycling, the product is 
treated with Dpn I. The Dpn I endonuclease (target sequence: 5´-Gm6ATC-3´) is 
specific for methylated and hemimethylated DNA and is used to digest the parental 
DNA template and to select for mutation-containing synthesized DNA. The nicked 
vector DNA incorporating the desired mutations is then transformed into XL10-Gold 
ultracompetent cells. 
 
Mutants were selected and sent for sequencing (CAF, Stellenbosch University) to 
verify the integrity of the DNA as well as mutation of the correct base pair.   
 
 
3.3.2 CD11b I-Domain 
 
The CD11 vector construct (known as pGEXCD11bI) was kindly donated by Dr. 
Sang-Uk Nham (Kangwon National University, Korea) and consists of a pGEX vector 
(Pharmacia Biotech., U.S.A.) containing the I-domain of CD11b, a GST tag for 
affinity purification, and an ampicillin resistance marker. The pGEXCD11bI vector 
was generated by subcloning the CD11b I-domain coding sequence, using BamHI 
and NotI restriction sites, into a pGEX-5T-3 vector and is predicted to be 5609 bp in 
size. The vector was isolated using a NucleoSpin® Plasmid kit (Macherey-Nagel, 
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Germany) and confirmed via the polymerase chain reaction (section 3.3.1.2) as well 
as restriction digestion (section 3.3.1.5).  
 
 
3.3.3 CD23 and mCD23 
 
The pET-28 vectors containing the insert sequences for soluble 25kDa CD23 
(sCD23) and mutant CD23 (mCD23) were donated by Dr Brodie Daniels (NMMU) 
and Melanie Pereira (NMMU), respectively.  
 
The sCD23 construct (p28sCD23His) has a hexa-histidine (His) tag for affinity 
purification and a kanamycin resistance marker. The sCD23 insert has an open 
reading frame encompassing residues Met150 – Ser321 and was subcloned in the 
XhoI and NcoI restriction sites of a pET-28b (+) vector to form the expression 
plasmid, p28sCD23His. It is predicted to be 5800 bp in size. 
 
Based on the hypothesis that the sCD23 interaction surface for β2 integrins (ie 
CD11/CD18) involves a particular RKC-motif located in the lectin head domain 
region of the sCD23 protein, a mutant version of this RKC-motif was produced to 
distinguish if there were any differences in binding involving the wild type RKC-motif 
or the mutant version (in this case AAC) of this motif. The peptide region containing 
the amino acid sequence INFQRKCYYFG (residues 168 to 178) was mutated to 
INFQAACYYFG to create mCD23 via site directed mutagenesis. The mCD23 
expression plasmid was isolated using a NucleoSpin® Plasmid kit and confirmed via 
the polymerase chain reaction as in section 3.3.1.2. 
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3.4 Results and Discussion 
3.4.1 Cloning of the CD18 β I-Like Domain 
 
In the case of CD18 ILD, the wild-type (WT)gene employs tandem rare codons that 
can reduce the efficiency of translation or even disengage the translational 
machinery. GenScript synthetically changed the codon usage bias in E. coli by 
upgrading the Codon Adaptation Index (CAI) from0.68 to 0.88. A CAI of 1.0 is 
considered to be perfect in the desired expression organism, and a CAI of > 0.8 is 
regarded as good, in terms of high gene expression level. 
 
GC content and unfavourable peaks were optimized to prolong the half-life of the 
mRNA. The Stem-Loop structures, which impact ribosomal binding and stability of 
mRNA, were broken and Dyad and Inverted repeats removed. In Dyad repeats, the 
two reverse complementary sequences will fold and base-pair with each other, the 
sequence of bases between them form a hairpin loop. This structure is thought to 
destabilize the binding of RNA polymerase enzyme to DNA (hence terminating 
transcription). In addition, the optimization process has screened and successfully 
modified negative cis-acting sites. Analysis in silico reveals large changes to the 
nucleotide sequence during codon optimisation but no change in the final amino acid 
sequence. The DNA and protein alignments can be seen in Figures A1 and A2 in 
Appendix A. 
 
The WT CD18 ILD coding sequence was PCR amplified and, concurrently with the 
CD18 ILDopt coding sequence, digested and ligated for construction of the 
p42CD18ILD and p42CD18ILDopt expression vectors. 
 
The WT CD18 ILD was PCR amplified (Figure 3.4) with the primers discussed in 
section 3.3.1.1 using Plasmid 8638 Integrin beta 2-mYFP as the template. 
Optimisation of the annealing temperature was performed which revealed 55°C as 
the optimum temperature at which the primers anneal to the target. This was shown 
as a more intense band at 55°C within the range of experimental temperatures (data 
not shown).  
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Figure 3.4: PCR amplification of the CD18 I-Like domain coding region using (A): Plasmid 
8638 Integrin beta 2-mYFP as the template DNA and (B): the primers as indicated. Agarose 
gel electrophoresis, together with a Generuler 1kb marker, yields a band at approximately 
791bp, corresponding with the expected size of the CD18 ILD amplicon, as shown in B. 
 
After successful amplification of the 791bp CD18 ILD-encoding fragment (Figure 
3.4), restriction digestion of the PCR product, the CD18ILDopt coding fragment as 
well as the pET42b vector was performed using XhoI and HindIII as described in 
Section 3.3.1.5. The cohesive termini produced via restriction endonuclease 
digestion then allowed for ligation of vector to insert, using T4 DNA ligase, resulting 
in two new vectors designated p42CD18ILD and p42CD18ILDopt (Figure 3.5). 
 
The vectors were used for heat shock transformation of E. coli (DH5α) cells used as 
the cloning strain. The putative transformants were plated on LB agar containing 
kanamycin to select for positive transformants. Colonies were selected and used for 
colony PCR as well as to inoculate overnight cultures in 5ml LB broth. Colony PCR 
was performed as described in Section 3.3.1.7 and colonies with a positive result 
showed a band of the correct size when analysed via agarose gel electrophoresis. 
The positive clones, corresponding to the equivalent overnight cultures, were then 
used for plasmid isolation and subsequently restriction endonuclease digestion as 
described in Section 3.3.1.7 and 3.3.1.5, respectively. Restriction digestion of 
p42CD18ILD and p42CD18ILDopt vectors using HindIII and XhoI results in 
fragments of about 777bp and 5914bp. 
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Figure 3.5: Vector Map and screen for clones analysed via agarose gel electrophoresis. (A) 
Vector map of p42CD18ILD/opt which was cloned and used to transform chemically 
competent E. coli and the screen for clones;(B) Colony PCR showing one negative result 
(Lane 1) and two positive clones (Lanes 2 & 3) of ~30 screened and (C) Restriction digestion 
using HindIII and XhoI showing correct size fragments of about 777bp and 5914bp from 
three putative clones out of 28 positives screened via colony PCR. 
 
Colony PCR was used for high-throughput screening of putative clones. Any number 
of colonies can be selected and individually added to premixed PCR reaction mix for 
a fast and efficient method to screen for clones. Positive results are indicated as a 
band of the correct size when analysed via AGE. The gel observed in Figure 3.5 
shows one negative result and two positive results. Of the ~30 colonies subjected to 
colony PCR, only 2 were negative. This indicates a high cloning and transformation 
efficiency. The positive clones were subjected to plasmid isolation and restriction 
digestion as a secondary confirmation before being sent for sequencing (CAF, 
Stellenbosch University).  
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The sequencing results were analysed using BLAST and DNA and protein 
alignments to assess for potential experimental mutations. A single clone each was 
selected for the CD18ILD and CD18ILDopt which showed no mutations from the 
sequencing data and these clones were used for further experimental analysis. 
These clones were used for site-directed mutagenesis in order to produce the 
mutation seen in LAD patients (S116ΔP) as well as the non-polar alternative 
(S116ΔA).   
 
3.4.2 Site Directed Mutagenesis 
 
The confirmed vectors p42CD18ILD and p42CD18ILDopt were used for site-directed 
mutagenesis, as described in Section 3.3.1.8, using the primers listed in Table 3.5. 
The vectors were thermo-cycled together with the mutagenic primers, as shown in 
Table 3.7, followed by Dpn1 digestion of the parental methylated and 
hemimethylated DNA, and then used to transform UltraGold competent cells before 
being plated on LB agar for overnight incubation at 37°C. Colonies were selected 
and sent for sequencing to confirm the correct mutation had indeed occurred. Figure 
3.6 shows a partial electropherogram and the protein alignment of the translated 
sequence obtained from the CAF, Stellenbosch University. 
 
Confirmed mutants (S116ΔP) and (S116ΔA), as well as each vector, p42CD18ILD 
and p42CD18ILDopt, were then used to transform chemically competent E. coli 
BL21 (DE3) for the expression of recombinant proteins CD18ILD, CD18ILDopt and 
two serine 116 mutants of each 
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Figure 3.6: Partial electropherogram and protein alignment from translation of the 
sequencing results for mutant S116∆P.(A) The mutated nucleotides are blocked in red, CCC 
is the codon for proline. (B) The alignment shows the correct mutation of serine to proline in 
red as well as the MIDAS site highlighted in yellow. 
 
.  
3.4.3 Verification of Vectors for Expression of CD23 and CD11b I-domain 
 
The previously cloned vectors for the coding regions of CD11b I-domain, CD23 
(25kDa) and mCD23 (RKCΔAAC), as well as empty pET42b, were isolated from 
glycerol stocks using a plasmid isolation kit. The plasmids were PCR amplified using 
vector primers (results not shown) for verification of the coding region. All vectors 
were successfully isolated using the plasmid isolation kit and PCR analyses revealed 
bands of the correct size thus verifying the integrity of the vectors and the coding 
regions. The vectors were used to transform chemically competent E. coli BL21 
(DE3) cells for expression of recombinant proteins. 
 
Original      LRPGQAAAFNVTFRRAKGYPIDLYYLMDLSYSMLDDLRNVKKLGGDLLRALNEITESGRI 
Sequenced     LRPGQAAAFNVTFRRAKGYPIDLYYLMDLSYPMLDDLRNVKKLGGDLLRALNEITESGRI 
******************************* **************************** 
 
Original      GFGSFVDKTVLPFVNTHPDKLRNPCPNKEKECQPPFAFRHVLKLTNNSNQFQTEVGKQLI 
Sequenced     GFGSFVDKTVLPFVNTHPDKLRNPCPNKEKECQPPFAFRHVLKLTNNSNQFQTEVGKQLI 
              ************************************************************ 
 
Original      SGNLDAPEGGLDAMMQVAACPEEIGWRNVTRLLVFATDDGFHFAGDGKLGAILTPNDGRC 
Sequenced     SGNLDAPEGGLDAMMQVAACPEEIGWRNVTRLLVFATDDGFHFAGDGKLGAILTPNDGRC 
              ************************************************************ 
 
Original      HLEDNLYKRSNEFDYPSVGQLAHKLAENNIQPIFAVTSRMVKTYEKL 
Sequenced     HLEDNLYKRSNEFDYPSVGQLAHKLAENNIQPIFAVTSRMVKTYEKL 
              *********************************************** 
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4 EXPRESSION AND PURIFICATION OF RECOMBINANT 
PROTEINS 
 
4.1 Introduction 
 
Target genes are first cloned using hosts that do not contain the T7 RNA polymerase 
gene in order to suppress expression of the recombinant protein. Suitable strains for 
cloning include E. coli K-12 strains DH5α and JM109. These strains are convenient 
for cloning as they are recA- and endA- which means that the DNA introduced into 
the host cell will not be destroyed by the bacterium’s DNA repair mechanisms. These 
strains also have high transformation efficiencies and good plasmid yield (Baneyx, 
1999). 
 
When protein expression is required, the recombinant plasmid is then introduced into 
an E. coli expression strain which contains a chromosomal copy of the gene for T7 
RNA polymerase. These hosts are lysogens of the bacteriophage DE3, a lambda 
derivative that has the immunity region of phage 21 and carries the fragment 
containing the lacI gene, the lacUV5 promoter and the gene for T7 RNA polymerase. 
Once the DE3 lysogen is formed, the only promoter known to direct transcription of 
the T7 RNA polymerase is the lacUV5 promoter, which can be induced by isopropyl-
β-D-thiogalactopyranoside (IPTG). By adding IPTG, the lysogen induces production 
of T7 RNA polymerase which then transcribes the target DNA in the plasmid (Studier 
et al., 1990). 
 
 
4.1.1 Inclusion Bodies 
 
A common feature of using E. coli for high expression of recombinant protein is the 
production of inclusion bodies, which are dense and amorphous protein deposits that 
can be found in bacterial cytoplasmic or periplasmic space. A major disadvantage is 
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that the inclusion bodies (IB) need to be isolated, renatured and refolded. IB’s are 
formed intracellularly either due to the aggregation characteristics of the protein or 
due to the inability of the cellular processes to correctly solubilise or fold the protein 
(Middleton, 2002). There are, however, advantages in the production of recombinant 
proteins in this manner. Often the recombinant protein is unstable if produced in the 
E. coli cytoplasm due to proteolysis and may also prove toxic to the host cell, thereby 
affecting the expression levels of the protein. Also, the expressed protein is often 
protected from proteases in this form. The relative high density of IB‘s also makes it 
easier for their isolation from other cellular proteins by centrifugation to yield highly 
concentrated and relatively pure protein (Hober and Uhlen, 1999). 
 
The main objective once the inactive and misfolded IB‘s are obtained is to convert 
them into soluble, biologically active products. The first step to achieve this is 
therefore to purify the IB’s by washing with a detergent. Detergents such as n-
dimethyldodecylamine N-oxide (LDAO), Triton-X-100 or low molar concentration of 
chaotrophs can be used for this purpose. Next, the purified IB‘s need to be 
solubilised using a strong denaturant such as 6M guanidinium hydrochloride (Gdn-
HCl) or 8M urea. However, Gdn-HCl is usually preferred to urea because it is a 
stronger chaotroph in that it is able to solubilize extremely aggregated IB‘s whereas 
urea may not solubilise the aggregates. In addition, urea solutions may also contain 
isocyanate which may lead to carbamylation of free amino groups of the polypeptide 
(Misawa and Kumagai, 1999).  
 
The addition of thiol agents such as β-mercaptoethanol or reduced glutathione 
(GSH) allows the reduction of disulphide bonds via thio-disulphide exchange which 
facilitates the solubilisation of cysteine containing compounds. After solubilisation of 
the IB‘s, in order to obtain correctly folded proteins, excess denaturants and reducing 
thiol reagents need to be removed, which can be achieved via dialysis, 
chromatography, or dilution. For the renaturing to be efficient there has to be 
competition between the correct folding and aggregation. To slow down the 
formation of aggregates, the refolding process is usually performed at low protein 
concentrations of 10–100 μg/mL. Furthermore, renaturation conditions need to be 
optimised with regard to factors such as temperature, pH and ionic strength for each 
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individual protein. Other parameters, such as the presence of low molecular weight 
compounds containing calcium (Ca2+) or NaCl in the renaturation buffer may also 
have a significant effect on the renaturation yield (Lilie et al., 1998).  
 
If the target protein contains disulfide bonds then the renaturation buffer has to be 
supplemented with a redox system such as reduced glutathione (GSH) and oxidized 
glutathione (GSSG) or other reduced and oxidized forms of low molecular weight 
thiol reagents in molar ratios of 5:1 to 10:1. This provides the appropriate redox 
potential to allow the formation of thiol bonds by following rapid reshuffling of 
incorrect disulfide bonds. By maintaining the pH of the renaturation buffer within the 
upper limit, it will accelerate thiol-disulfide exchange, which will assist the 
renaturation of the recombinant protein (Misawa and Kumagai, 1999). 
 
Once the protein has been expressed and the inclusion bodies, or the soluble 
protein, have been extracted from host cells, the recombinant protein needs to be 
isolated and purified from the contaminating endogenous host proteins. The most 
common method used for this process is chromatography. A pure preparation is 
essential before a protein’s properties and activities can be determined. Methods for 
separating proteins take advantage of properties that vary from one protein to the 
next, including size, charge and binding characteristics (Nelson and Cox, 2005). 
Many proteins are cloned with a fusion/affinity tag to facilitate purification.     
 
 
4.1.2 Affinity tags 
 
The use of affinity tags enables a more simple and easy purification process. Not 
only does the use of affinity tags decrease the number of chromatographic isolation 
steps, but it usually results in a higher yield of pure protein, decreased proteolysis 
and increased solubility. Tags can, however, change the protein conformation, lower 
protein yields, inhibit enzyme activity, alter biological activity and cause toxicity. 
Polyhistidine (His) tags are a 6 histidine polypeptide, cloned to one terminus that 
allows purification of the fusion protein via nickel affinity residues. These are the 
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most widely used affinity tags because they are small and often do not interfere with 
folding of the desired protein. It also shows very strong reversible binding to chelated 
metals, therefore making the purification process faster (Hunt, 2005). An alternative 
affinity tag is glutathione S-transferase (GST) of Schistosoma japonicam; first cloned 
into an E. coli expression vector in 1988 (LaVallie and McCoy, 1995; Yasukawa et 
al., 1995; Smith and Johnson, 1988). 
 
Yield of fusion protein is highly variable and is affected by the nature of the fusion 
protein, the host cell, and the culture conditions used. GST fusion proteins can be 
purified from bacterial lysates via affinity chromatography using immobilised 
glutathione on a matrix support (such as Sepharose or agarose) via the enzyme-
substrate binding reaction. GST fusion proteins are captured by the affinity medium 
and impurities are removed by washing with a suitable buffer. One of the most 
important parameters affecting the binding of GST fusion proteins to its matrix 
support is the flow rate. Since the binding kinetics between glutathione and GST are 
relatively slow, it is important to keep the flow rate low during sample application to 
achieve maximum binding capacity.  
 
The binding properties of the target protein can be improved by adjusting the sample 
to the composition of the binding buffer. Reduced glutathione (in excess) is used to 
elute GST fusion proteins under mild non-denaturing conditions whereby protein 
antigenicity and function is preserved. Bound protein is easily dissociated (eluted) by 
competitive displacement with buffer containing free, reduced GSH (oxidized 
glutathione, GSSG, is not effective for this purpose). Cleavage of the protein from 
GST is optional and can be achieved by using site-specific proteases whose 
recognition sequence is situated immediately upstream from the MCS on the 
plasmid. The fusion protein can be detected using colourimetric or immunological 
methods (GST Gene Fusion System Handbook). 
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4.2 Materials 
The E. coli BL21 (DE3) expression strain was obtained from Novagen (USA). The 
HD2200 Sonopuls probe sonicator was obtained from Bandelin Electronics GmbH 
(Germany). FPLC work was performed on an ÄKTA FPLC with a Superdex75 
(16/60) column, obtained from GE HealthCare Life Sciences (UK).Pierce® GST Spin 
Purification Kit (Catalog #16106) was purchased from Thermo Scientific (USA). 
Antibodies were obtained from Calbiochem; anti-GST rabbit polyclonal antibody 
(catalogue number PC53) and anti-rabbit IgG conjugated to horseradish peroxidase 
(catalogue number DC03L).  
 
 
4.3 Methods 
 
4.3.1 SDS PAGE and Protein Quantification 
Separation of proteins by SDS-PAGE was carried out according to Laemmli (1970), 
where a final concentration of 15% (v/v) acrylamide was used in all gels.  
 
Protein concentration was quantified using the NanoDrop 2000c (Thermo Fischer 
Scientific) using a general reference setting based on a 0.1% (1 mg/mL) protein 
solution producing an absorbance at 280 nm of 1.0 (where the pathlength is 1cm). 
 
 
4.3.2 Recombinant Protein Expression 
 
The purified plasmids were used to transform chemically competent E. coli BL21 
(DE3) cells for the expression of CD18 ILD and two mutants, CD18 ILDopt and two 
mutants, CD11b I-domain, CD23, mCD23, as well as GST as a control.   
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4.3.2.1 Test expression of recombinant proteins 
 
Test expressions of the recombinant proteins were carried out by inoculating 5 mL 
LB broth (with appropriate antibiotic) with a single colony followed by overnight 
incubation at 37 ºC with constant shaking at 180 rpm on an orbital shaker. A 500μL 
aliquot of the overnight culture was used to inoculate 50 mL prewarmed LB broth, 
containing the appropriate antibiotic, followed by incubation at 37 ºC with rotation at 
180 rpm. The absorbance at 600 nm was monitored and once the OD600 reached 0.5 
- 0.7, the cells were harvested by removing 1mL to a sterile Eppendorf tube and the 
cells were pelleted by centrifugation and the supernatant discarded. This dried pellet 
represented the pre-induction sample and was stored at -20 ºC and later 
electrophoresed on a 15% SDS-PAGE gel under reducing conditions. After removal 
of the pre-induction sample, protein expression was induced in the remaining 50 mL 
of culture by adding IPTG to a final concentration of 1 mM from a 1 M filter sterilized 
stock. Growth was further monitored by taking absorbance readings at 600 nm at 1, 
2, 3 and 4 hours after induction. At each of these time intervals, another 1mL of 
sample was removed and the cells pelleted as before, for later use in 
electrophoresis.  
 
Once all the samples were obtained, the cell pellets were loosened and 100 times 
the OD600 of double-strength Laemmli (1970) SDS-PAGE reducing sample buffer 
was added and heated at 95 ºC for 10 minutes to completely lyse cells before 
executing SDS-PAGE.  
 
 
4.3.2.2 Preparative expression of recombinant proteins 
 
Preparative expression of protein was performed exactly as for test expression, 
except that 4 x 1 L cultures were induced with 1 mM IPTG for the optimal time 
established by the test expressions, which was 3 hours for both the wild type and 
mutant CD23 and 2 hours for CD18 and CD11b I-domain.  
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Cells were harvested by centrifugation at 5500 x g for 20 minutes at 4 ºC in a 
Beckman Avanti-J25 centrifuge. The cell pellet from 1 L of culture of CD23 was 
resuspended in 10 mL of sonification buffer (50 mM Tris-HCl, pH 7.8, 0.3 M NaCl 
and 0.2% NaN3) and stored at -80 ºC in 50 mL Falcon tubes. Similarly, the cell pellet 
from 1 L culture of CD18 and CD11 b I-domain was resuspended in 10 mL I-domain 
isolation buffer (20 mM Tris-HCl, 10 mM EDTA, pH 7.5) and stored at -80 ºC in 50 
mL Falcon tubes. 
 
4.3.3 Purification of CD18 β I-Like domain and CD11b I-domain 
4.3.3.1 Affinity chromatography 
 
The cells harvested from expressions were thawed, combined and ruptured by 
sonication using a Bandelin Sonopuls HD2200. Keeping the samples on ice, 
samples were sonicated for six bursts of 45 seconds, pulsing at 50% duty cycle and 
40% power followed by centrifugation at 4 ºC for 30 minutes at 4000 x g in an 
Eppendorf 5804R centrifuge fitted with an A-4-44 rotor. The supernatant was 
retained and further concentrated to between 5-10 mL using Amicon Ultracentrifugal 
filters. This concentrated protein solution was filtered using a 0.45 μm syringe filter 
and loaded onto two 1 mL GSTrap FF columns linked in series (for scale-up 
purposes) in combination with an ÄKTA FPLC. GSTrap columns (2 mL) were 
washed with 5 column volumes of equilibration buffer (20 mMTris/HCl, pH 8.0) at 2 
mL/min, before the sample was injected. It has previously been shown that the 
interaction between GST and the glutathione-Sepharose of the column is slow (Alm, 
2010). The flow rate was decreased to 0.5 mL/min while the sample was being 
injected. The column was washed with 5 column volumes of equilibration buffer to 
remove any unbound protein. The GST-tagged bound protein was eluted with I-
domain elution buffer (15 mM reduced glutathione in 20 mM Tris/HCl, pH 8.0). The 
fractions containing the eluted protein were collected and dialysed against two 
changes of phosphate buffered saline (PBS) to remove any glutathione. The dialysis 
and concentration was carried out using Amicon Ultra 15 Centrifugal Filters and the 
protein was stored at -20 ºC. 
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4.3.3.2 Spin column purification 
 
We primarily made use of a GST Spin Purification Kit. Sample application, washing, 
and elution were performed according to manufacturer‘s instructions (Pierce® GST 
Spin Purification Kit).  The procedure entailed application of the GST-tagged CD11b 
I-domain and CD18 ILD cell lysate to prepacked spin columns; where the column 
support consists of glutathione that has been immobilized through its central 
sulfhydryl group via a 12-atom spacer arm to crosslinked 6 % beaded agarose. The 
applied GST-tagged protein binds specifically to the affinity medium where after 
impurities were removed by washing with 125mM Tris, 150mM NaCl, pH 8.0. Bound 
protein was eluted by competitive displacement with buffer containing free, reduced 
GSH (125mM Tris, 150mM NaCl, 10mM GSH, pH 8.0). The technique thus provides 
a mild purification process that does not affect a protein‘s native structure and 
function.  
 
4.3.3.3 Western blotting 
 
Western blotting is a technique used for the analysis of individual proteins in a 
heterogenous protein sample, i.e. a cell lysate. Initially the protein mixture is applied 
to gel electrophoresis in a carrier matrix (such as SDS-PAGE, isoelectric focusing, 
2D-PAGE etc.) in order to separate the proteins into individual bands according to 
size, charge etc. The next step involves transferring the separated protein bands to a 
carrier membrane such as nylon, nitrocellulose or polyvinylidene difluoride (PVDF). 
This process is called blotting. Due to hydrophobic and/or ionic interactions, the 
proteins adhere to the membrane in the same pattern as they have been separated. 
The membrane is then blocked to prevent any non-specific binding of antibodies to 
the surface of the membrane. Most commonly, the transferred protein is then 
complexed with an enzyme-labelled antibody as probe and once an appropriate 
substrate is added to the antibody conjugate, a detectable product (such as a 
chromogenic precipitate) is produced on the membrane for colourimetric detection. 
Alternatively, fluorescently tagged antibodies can be used which are directly 
detected with the aid of a fluorescence imaging system (Burnette, 1981). 
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Proteins that were separated using SDS-PAGE (performed in 10% acrylamide gel) 
were transferred to an Immobilon PVDF membrane for Western Blotting. After 
electrophoresis, the SDS-PAGE gel was placed in transfer buffer (48 mM Tris, 39 
mM glycine, 20% (w/v) methanol) for 20 minutes to allow for the equilibration of the 
gel. A piece of Immobilon PVDF membrane, the size of the gel was pre-wet in 10 mL 
100% methanol for 5 seconds followed immediately with soaking in 500 mL dH2O for 
10 minutes to remove the methanol. The membrane was equilibrated for 20 minutes 
in 500 mL transfer buffer. Six pieces of blotting paper were also equilibrated in 
transfer buffer.  
 
The blotting cassette was assembled as explained in the Bio-Rad instruction manual 
for the Transblot® SD semi-dry electrophoretic cell. The sandwich was stacked in 
the order of 3 pieces of thick blot paper, membrane, gel and three pieces of thick blot 
paper. Air was removed from between the layers after each layer was stacked. The 
cathode was connected on top of the sandwich followed by the safety cover. The 
transfer was carried out at 25 V with a constant current of 5 mA/cm2 for 2 hours.  
 
For immunodetection of recombinant proteins, blocking was carried out by placing 
the membrane in blocking buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.05% 
Tween-20 and 5% non-fat milk powder) for ≤16 hours at 4°C. Once blocked, 
membranes were washed in TBST (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.5% 
Tween-20) and exposed to primary antibody (Table 4.1), diluted in blocking buffer, 
for 1 hour at room temperature.  This was followed by several washes in TBST and 
exposure to the relevant secondary antibody (Table 4.1), for 1 hour at room 
temperature. Unbound secondary antibody was removed by washing in TBST and 
detection carried out by adding TMB substrate. 
 
Table 4.1: Antibodies used in Western blotting 
Protein Target Primary/Secondary Antibody Dilution 
CD18 ILD GST 
Primary 
anti-GST rabbit 
polyclonal 
1 : 10 000 
Secondary 
anti-rabbit IgG 
conjugated to HRP 
1 : 20 000 
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4.3.4 Purification of CD23 and mCD23 
4.3.4.1 Inclusion body isolation 
 
The cells harvested from expressions were thawed and sonication buffer was added 
if necessary to dilute. Lysozyme (1mg/mL) was added and incubated at room 
temperature for 30 minutes, mixing end-over-end. The cells were chilled and 
sonicated on ice for six bursts of 45 seconds, pulsing at 50% duty cycle and 40% 
power with a Bandelin Sonopuls HD2200 sonicator. The cells were centrifuged at 25 
000 x g for 40 minutes at 4 ºC using a Beckman Avanti JA25 centrifuge. The pellet 
was resuspended in approximately 15 ml of inclusion body wash buffer [50 mM Tris-
HCl, pH 7.8, containing 0.3 M NaCl, 0.5% N, N–dimethyldodecylamine N-oxide 
(LDAO), 0.2 % NaN3]. A Potter-Elvejham homogeniser was used to resuspend the 
inclusion bodies in IB wash buffer, with 5 – 6 strokes on ice. The washes were 
pooled and centrifuged as before, keeping an aliquot of the wash supernatant for 
analysis by SDS-PAGE. The inclusion bodies were continuously washed until most 
of the E. coli proteins were removed. The washed inclusion bodies were 
resuspended in 4-5 ml of sonication buffer and stored at 4 ºC. 
 
4.3.4.2 Refolding using rapid dilution technique 
 
The refolding procedure was performed as described by Daniels et al. (2005). A 
protein stock was prepared from the IB preparation by diluting 1:2 with inclusion 
body dissolving buffer (20 mMTris-HCl, pH 8.0, 6 M guanidinium hydrochloride). β-
mercaptoethanol was added to a final concentration of 100 mM. The protein stock 
was added to the refolding buffer (100 mM Tris, 150 mM NaCl, 1.5 M arginine, 10 
mM CaCl2, 5 mM GSH and 0.5 mM GSSG, pH 8) by very slow dropwise additions at 
4 ºC, with stirring of the refolding buffer, such that the protein stock is diluted 1:100 in 
the refolding buffer by volume (i.e. a 5 mL protein stock is added to 500 mL refolding 
buffer). The redox potential was monitored from day 1 (Section 4.3.4.3) until it was 
below 1 mM (approx. 3 days), with continuous stirring of the refolding mixture at 4 
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ºC. The refolding buffer was removed by overnight dialysis at 4 °C against PBS (8g 
of NaCl, 0.2g of KCl, 1.44g of Na2HPO4 and 0.24g of KH2PO4/ L, pH 7.4). The 
protein solution was concentrated (~10mL) using an Amicon stirred ultrafiltration cell 
(Millipore) with a Millipore 5 kDa molecular weight limit regenerated cellulose 
ultrafiltration disc. 
 
4.3.4.3 Measurement of redox potential 
 
Ellman’s reagent was first used for the estimation of free thiol groups in 1959. This 
method is based on the reaction of the thiol with 5, 5’-dithiobis (2-nitrobenzoic acid) 
(DTNB) to give the mixed disulphide and 2-nitro-5-thiobenzoic acid (TNB) that can 
be quantified by absorbance at 412 nm (Aitken and Learmonth, 1996). DTNB allows 
one to conveniently follow the folding of proteins by reaction of their free thiol groups 
(Ramachandran et al., 2000). A microplate method, using DTNB, was utilised to 
determine the redox potential of the refold buffer (Bowles, 2010). A small aliquot of 
the refold buffer (2.5 µL) was added to 12.5μL of 1 M Tris (pH 8.0) and 1 μL of 100 
mM DTNB. The mixture was made up to a final volume of 250 μL with distilled water 
and measured at 412 nm with the PowerWave HT Microplate Spectrophotometer 
(BioTek). The molar extinction coefficient of 13 600 cm-1.M-1 was used to calculate 
redox potentials from absorbance values using the following equation:  
 
Redox potential (mM) = (OD412/13 600 M-1cm-1) x 1000 x dilution factor* 
*dilution factor was 125in this case  
 
 
4.3.4.4 Purification of recombinant human CD23 
 
After refolding, the concentrated protein solutions were passed through a Superdex 
75 (16/60) gel filtration chromatography column using an ÄKTA FPLC. This was 
done by injecting a 2 mL sample of the protein with a flow rate of 2 mL per minute 
with 10mM HEPES, pH 7.4 as eluent. The fractions collected were ~5 mL in volume 
and the relevant peaks were pooled and concentrated using Amicon Ultra 15 
Centrifugal Filters and the protein stored at -20 ºC. 
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4.4 Results and Discussion 
4.4.1 Expression and purification of CD11b I-domain and CD18 I-Like Domain 
Expression of the CD11b I-domain was carried out in E. coli BL21 (DE3) cells, as 
described by Daniels (2010) (Section 4.3.1.2). Pre- and post-induction samples were 
analysed by SDS PAGE (results not shown) and found to contain clear bands of the 
correct size, ~50kDa, which indicated successful expression of the recombinant 
CD11b I-domain. The protein was extracted from the bacteria by sonication and 
centrifugation. The supernatant was concentrated before isolation and purification 
using a GSTrap column in combination with an ÄKTA FPLC. 
 
On the chromatogram (data not shown), the first peak is known as the fall-through 
peak and contains contaminating E. coli proteins. The contaminating proteins were 
washed off the column with equilibration buffer. Elution buffer containing 10 mM 
GSH was pumped through the column. The GSH competitively displaces the GST-
fusion and the protein is then eluted. However, in this instance, a second peak was 
not visualised. According to Daniels (2010) and Pereira (2012), the second peak 
elutes at approximately 25ml, consequently the corresponding tubes were collected, 
concentrated and analysed with SDS-PAGE to check for the presence of CD11b I-
domain protein.  
 
The chromatogram and SDS PAGE analysis are not shown due to the total absence 
of a peak or band of the correct size in the elution fraction. The recombinant protein 
was eluted in the fall-through peak and not retained on the column for elution by 
GSH. The reason for this may be due to the expiration of the columns and their 
failure to bind GST or the very slow binding kinetics involved. It has previously been 
shown that the interaction between GST and the glutathione-Sepharose of the 
column is slow (Harper and Speicher, 2011) and, although the flow rate was 
decreased to 0.5 mL/min while the sample was being injected, this may have still 
been too fast. Hence we made use of a GST Spin Purification Kit from Pierce.  
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Test expression of recombinant CD18 ILD and CD18 ILDopt molecules was carried 
out in E. coli BL21 (DE3) cells (Section 4.3.1.1). Aliquots were collected before and 
after induction and analysed by SDS-PAGE to determine if the proteins were 
successfully expressed (Figure 4.1). A comparison between induced and uninduced 
samples revealed that both recombinant CD18 molecules were successfully 
expressed. Both induced samples contained intense bands of the appropriate sizes 
(~50kDa) with little to no difference observed in expression levels between CD18 ILD 
and ILDopt, when analysing the whole cell lysates. Native GST is approximately 
26kDa; however, parental GST vectors produce a 29kDa GST fusion protein 
containing amino acids coded for by the multiple cloning site of the vector (GST 
Gene Fusion System Handbook). GST was expressed and analysed by SDS-PAGE 
(Figure 4.1) as a positive control.  
 
Figure 4.1: SDS-PAGE analysis of CD18 ILD and CD18 ILDopt test expression. Whole cell 
lysates were analysed at pre- and post-induction at 2,3 and 4 hours as indicated for each 
protein. A band at ~50kDa indicates CD18 I-Like domain recombinant protein. GST (29kDa) 
was expressed and analysed as a positive control. 
 
Confirmation of expression of the CD18 ILD and CD18 ILDopt permitted preparative 
expression. We decided to continue only with the optimised CD18 I-Like domain for 
a number of reasons, including time constraints, redundant expression of the same 
protein and, from Figure 4.1, very little difference shown in expression levels. 
Therefore, in order to increase the likelihood of expressing soluble recombinant 
protein, the codon optimised sequence was the clear choice for expression in E. coli. 
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Preparative expression was carried out as described for the CD11bI-domain 
(Daniels, 2010) and recombinant protein was extracted from the bacteria by 
sonication and concentrated before isolation and purification using the GST Spin 
Purification kit. 
 
 
The GST Spin Purification kit was used to purify both the GST fusion proteins; 
CD11b I-domain and CD18 I-Like domain.  Sample application, washing, and elution 
were performed according to manufacturer‘s instructions. The results can be seen in 
figures4.2 and 4.3, where pre- and post-induction samples, washes and eluates are 
analysed via SDS PAGE for CD11b and CD18, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: SDS-PAGE analysis of GST Spin Column purification of CD11b I-domain. A pre- 
and post-induction sample was analysed for expression followed by the third wash of the 
purification procedure and the final lane shows the eluted CD11b I-domain (~50kDa). 
 
 
The CD11b I-domain recombinant protein was successfully expressed and purified 
using the GST Spin purification columns (Figure 4.2) as seen by the clear band at 
~50kDa. The GST Spin purification column appeared to yield a relatively high purity 
of protein as shown in the last lane by the lack of contaminating bands. The CD11b 
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I-domain recombinant protein yield was 6.26mg/L culture, sufficient to be used 
subsequently for binding studies (Chapter 5). 
 
SDS-PAGE analysis revealed that although CD18 ILD was successfully expressed, it 
was not clearly visible in the supernatant (soluble) fraction. Despite this fact, the 
supernatant was loaded onto the GST Spin column and elution carried out with 
10mM GSH.  
 
 
 
 
Figure 4.3: SDS-PAGE analysis of GST Spin column purification of CD18 I-Like domain. A 
pre- and post-induction sample was analysed for expression followed by the supernatant 
following sonication which represents the soluble fraction of proteins. The last three lanes 
indicate the purification procedure seen as; the second and third wash and the eluted 
CD18ILD, respectively. 
 
The results analysed using SDS-PAGE (Figure 4.3) showed an intense band at 
~26kDa for the eluted fraction, which correlates to the size of the GST fusion tag, but 
little or no band visible at ~50kDa for CD18 ILD. It was therefore decided to analyse 
the insoluble fraction via SDS-PAGE (Figure 4.4). 
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Figure 4.4: SDS-PAGE analysis of CD18 I-Like domain soluble and insoluble fractions. The 
position of the upregulated CD18 ILD (~50kDa) has been blocked for particular analysis 
across soluble and insoluble fractions. 
 
SDS-PAGE analysis of the soluble and insoluble fractions obtained post-sonication 
was inconclusive. Cell lysis protocols were amended in an attempt to increase the 
yield of recombinant protein. These included increasing sonication time in order to 
lyse more cells, decreasing sonication time to maintain integrity of recombinant 
proteins (GST Gene Fusion handbook) and additional freeze-thaw cycles. By 
increasing sonication time in the hope that more cells would lyse and the yield of 
recombinant protein would increase, the overall yield of soluble proteins increased 
with no apparent increase of recombinant proteins. The decreased sonication time 
only served to decrease the yield of all soluble proteins as cells were incompletely 
lysed. The additional freeze-thaw cycles showed no apparent change in yield of 
soluble proteins. These results were analysed by SDS-PAGE (not shown) and did 
not appear to enhance the yield of soluble recombinant CD18ILD protein. It was 
therefore decided to perform a Western Blot (Section 4.4.1.1) to detect if trace 
amounts of CD18 ILD were isolated or purified via the GST spin column. 
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4.4.1.1 Western Blot Analysis 
 
To confirm the expression, isolation and purification of C18 ILD, a Western blot was 
utilized as SDS-PAGE analysis was inconclusive. Western blotting revealed faint 
bands at ~50kDa (Figure 4.5) in the eluted fractions, alluding to the possibility that 
CD18 ILD was successfully purified, albeit in a small amount. A much stronger band 
was visible at ~26kDa, the size of the GST tag. This could indicate that the tag is 
being cleaved from the fusion protein via digestion by endogenous E. coli proteases 
or that translation is being prematurely terminated during expression. However, 
further analysis is required, particularly of the whole-cell lysates of pre- and post- 
induction and sonication, in order to determine whether cleavage or premature 
termination of translation is the case.  
 
Figure 4.5: Western blot analysis of CD18 ILD; using anti-GST rabbit polyclonal antibody 
(primary) and anti-rabbit IgG conjugated to HRP (secondary) to detect GST-fusion proteins. 
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At 26kDa, GST is considerably larger than many other fusion protein affinity tags. 
For reasons that have not been fully characterized in the literature, the structure of 
the GST fusion tag often degrades upon denaturation and reduction for protein gel 
electrophoresis (e.g., SDS-PAGE). As a result, electrophoresed samples of GST 
fusion proteins often appear as a ladder of lower molecular weight bands below the 
full-sized fusion protein. This may have been the case during SDS-PAGE analysis of 
CD18 ILD-GST fusion isolation and purification. Another consideration is dimer 
formation, which is inevitable with GST fusion proteins since GST itself is a 
homodimer when folded (Harper and Speicher, 2011). 
 
 
4.4.2 Expression of recombinant CD23 proteins and isolation of inclusion 
bodies 
 
 
Recombinant mutant CD23 vector, where the RKC motif was mutated to AAC, was 
used to transform chemically competent E.coli BL21 (DE3) cells. Mutant CD23 was 
subsequently expressed and purified as described in Section 4.3.3. Wild type CD23 
(25kDa) and derCD23 (16kDa) were received as a donation from Dwain Van Zyl 
(NMMU).  
 
Culture aliquots were collected before and after induction and analysed by SDS-
PAGE to determine ifmCD23 was successfully expressed (Figure 4.6). A comparison 
between induced and uninduced samples revealed that recombinant mCD23 protein 
was successfully expressed as induced samples contained intense bands of the 
appropriate size (25kDa).  
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Figure 4.6: SDS-PAGE analysis of expression of recombinant mCD23.Analysis of pre- and 
post-induction samples reveals upregulation of mCD23; shown as an intense band at 
~25kDa. 
 
Confirmation of 25 kDa mCD23 expression permitted the isolation of IBs. To obtain 
IBs, cells were lysed with freeze-thaw cycles, lysozyme and sonication (Section 
4.3.4.1). Insoluble fractions were collected by centrifugation and washed with buffer 
containing the detergent lauryldimethylamine oxide. With each wash more 
contaminating E. coli proteins were removed. After eight washes the bulk of E. coli 
proteins were removed from IBs (Figure 4.7). Consequently, the IBs obtained 
primarily consisted of 25kDa mCD23.  
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Figure 4.7: SDS-PAGE analysis of mCD23 Inclusion body isolation and purification. Purified 
inclusion bodies are shown in the last lane at ~25kDa. 
 
A large amount of relatively pure recombinant protein was obtained from the 
inclusion bodies. The expected size of the target protein is approximately 25 kDa, 
and as can be seen in Figure 4.7 (post induction and pure IB’s) the protein band 
obtained in the inclusion body preparation is in the correct size range. Figure 4.7 
clearly shows a reduction in contaminating E. coli proteins after each wash as well 
as a minimal loss in mCD23 protein, which was tolerable as each wash step 
improved the purity of the final preparation. The first few washes seemed to remove 
most of the contaminating E. coli proteins whereas subsequent washes did not 
remove large amounts of host protein. The purified inclusion bodies were solubilised, 
refolded and concentrated according to the method described by Daniels et al. 
(2005) before further purification via gel filtration chromatography. 
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4.4.3 Refolding and purification of recombinant mCD23 
IBs were dissolved in 6 M guanidinium hydrochloride in 20 mM Tris-HCl, pH 8.0, 
containing 0.2% NaN3 and added dropwise to the refold buffer at 4°C with gentle 
continuous stirring. The refolding of recombinant CD23 was monitored with DTNB 
until the redox potential dropped below 1mM. DTNB reacts with free thiols of 
cysteine residues to produce a coloured product observed at 412 nm. This provides 
a very convenient method to probe for structural changes in proteins in terms of 
disulfide bond formation (Ramachandran et al., 2000).  
 
Figure 4.8 shows the constant decrease in redox potential during the refolding 
process as an indication of whether the protein has refolded. Three days of refolding 
was required to reduce the redox potential to below 1 mM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8: Monitoring the refolding of CD23 via measurement of redox potential. The 
concentration of free thiols was determined by assaying with DTNB as an indication of the 
refold process and was monitored until below 1mM. 
 
After the mCD23 protein was refolded by rapid dilution it was dialysed against PBS 
to remove some of the harsh components in the dissolving buffer (i.e. 6 M 
guanidinium hydrochloride) and refold buffer (i.e. 1.5 M arginine). Subsequently, 
proteins were concentrated with ultrafiltration to a final volume of ~10 mL and 
separated by size exclusion chromatography on Superdex 75 16/60 (Figure 4.9).  
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Figure 4.9: Purification of refolded 25kDa mCD23 by gel filtration chromatography.Gel 
filtration was performed using a Superdex 75 16/60 column with 10mMHEPES (pH 7.4) as 
developing buffer at a flow rate of 2 mL/minute. Chromatogram showing the mCD23 
containing peak as well as incorrectly folded aggregates and redox couple peaks. Inset 
shows SDS-PAGE of eluted purified mCD23. 
 
The chromatogram obtained was highly comparable to those observed in previous 
studies (Daniels, 2003; Askew, 2005; Bowles, 2010; Pereira, 2012). Refolded 25kDa 
mCD23 (Figure 4.9) eluted at ~63mL which was substantially earlier when compared 
to the Superdex 75 26/60 column used by Pereira (2012) (Ve~150mL).Although 
longer gel filtration columns give higher resolution, the shorter elution time with the 
smaller 16/60 column yielded a higher resolution, seen as a sharper peak, possibly 
due to reduced on-column diffusion (GE Healthcare Superdex manual). Separation 
of 25 kDa mCD23 from unfolded aggregates was successful. Purification was faster 
with a much higher yield of recombinant protein per litre of culture. The final yield of 
purified 25kDa mCD23 was 11.65mg/L culture, where Pereira (2012) obtained 
2.75mg/L culture for mCD23 and van Zyl (2012) obtained 7.03mg/L and 8.17mg/L 
culture for 25kDa CD23 and derCD23, respectively.  
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5 BINDING BETWEEN CD11b I-DOMAIN AND CD23 
 
It is well known that β2 integrins have many ligands that they bind to, as described in 
Chapter 1. Many of these binding relationships have been investigated and 
characterised and the αI domains of CD11/CD18 integrins contain the recognition 
sites for most ligands of leukocyte integrins (Ihanas et al., 2003). However, while 
there is data available proving that CD11b and CD11c bind to CD23 (Lecoanet-
Henchoz et al., 1995), there is less data available on the recognition sites and 
kinetics involved in this interaction. This accordingly led to investigation of the 
interaction between CD23 and the CD11b I-like domain through surface plasmon 
resonance (SPR) spectroscopy 
 
 
5.1 Introduction 
5.1.1 Surface Plasmon Resonance Spectroscopy 
 
Since the late 1990's, SPR biosensors have become the main tool for the study of 
biomolecular interactions both in life science and pharmaceutical research. The SPR 
method is based on optical measurement of refractive index changes associated 
with the binding of analyte molecules in a sample to recognize molecules 
immobilized on the SPR sensor. SPR analysis is rather useful in that it allows assay 
of binding constants (affinity) and kinetic analysis of binding phenomena (Piliarak et 
al., 2009).  
 
SPR is an optical phenomenon that occurs when p-polarized light is reflected off a 
thin metal film (the gold film coated on the sensorchip) at a certain wavelength and 
angle, under the condition of total internal reflection (TIR). The light excites surface 
plasmons in the metal at a certain incident angle. The TIR field generates an 
evanescent wave in the thin metal film which propagates into the medium above the 
chip surface. The excited surface plasmons are very responsive to the refractive 
index change at the surface of the thin metal film. The incident angle of the light 
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required for SPR is impacted by the refractive index change caused by molecules in 
contact with the chip surface. In an SPR binding experiment, this refractive index 
change is brought about by binding of analyte in solution to ligand immobilized on 
the chip surface; therefore, tracking the change in the incident angle required for 
SPR allows biomolecular interactions to be monitored in real-time. The change of the 
incident angle required for SPR is defined as the SPR signal in response units (RU). 
One RU is 1/1,000,000 of a refractive index unit, and is approximately equivalent to a 
surface density of protein~1 pg/mm2 (Daghestani et al., 2010). 
 
 
5.1.2 ProteOn XPR36 
 
The ProteOn XPR36 system detects binding between a ligand immobilized on a 
sensor chip and an analyte flowing over it in a microfluidic channel using SPR 
technology. The real-time data generated by the ProteOn XPR36 System can be 
analysed using several different binding models for analysing kinetic data, ranging 
from a simple Langmuir model of 1:1 binding to more complex binding models such 
as Langmuir binding with mass transport limitations. The ProteOn system is 
particularly proficient at obtaining kinetic data due to the novel XPR™ technology, 6 
x 6 interaction array, on the ProteOn sensor chips. Based on this technology, the 
patented One-shot Kinetics™ approach uses the interrogation of six ligands with a 
series of up to six concentrations of one analyte in a single injection to investigate 
the kinetics of an interaction. The ProteOn can also be used to characterize epitopes 
on an antigen, investigate binding thermodynamics, screen small molecules for 
affinity, or to determine the active concentration of an analyte in a heterogeneous 
sample (Bio-Rad, 2014). 
 
SPR is used to detect the interaction between two unlabeled biomolecules in real-
time. A typical experiment involves immobilizing a ligand to a functionalized gold 
sensor chip and flowing an analyte over the chip surface to investigate the binding 
affinity and kinetics of the analyte to the ligand. Binding of analyte to the ligand is 
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tracked by following the change of SPR signal measured at the surface of the sensor 
chip over time, which is plotted as a sensorgram (Figure 5.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: Schematic illustration of the conversion of shift in SPR angle to sensorgrams 
(Cooper, 2002). 
 
Plotting the SPR signal over time during the interaction between an analyte and a 
ligand results in a sensorgram, a visual representation of the interaction over time. 
Figure 5.2 shows an example sensorgram. The binding response initially increases 
as analyte is flowed over the sensor chip and associates with the immobilized ligand. 
The response then decreases as the analyte solution is replaced with buffer and the 
binding complex dissociates. If binding equilibrium is reached during the association 
phase, the sensorgram will reach a constant plateau before dissociation. Fitting the 
sensorgram data to a binding model allows for the calculation of the association (ka) 
and dissociation (kd) rate constants and determination of the binding affinity (KD). 
Kinetic measurements with SPR usually involve sequential injections of analyte at 
increasing concentrations over the same ligand surface, which requires complete 
removal of the analyte, or regeneration of the ligand surface, between analyte 
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injections. In an ideal case, regeneration of the ligand surface is seen in the 
sensorgram as a sharp drop in RU after dissociation and a return to the original 
baseline. Regeneration is usually done with a combination of acids, bases, salts or 
dilute surfactants. Regeneration must be carefully planned or optimised to avoid 
denaturing or removing the immobilized ligand or removing ligand from the sensor 
chip (de Mol and Fischer, 2010). 
 
 
Figure 5.2:Example SPR sensorgram showing; the establishment of an initial baseline, an 
increase in response during association, a constant response after equilibrium/steady state 
is reached, and a decrease in response during dissociation. This is followed by regeneration, 
where there is decrease in response and a return to baseline (Ritzefeld and Sewald, 2011). 
 
 
Using enhanced microfluidic delivery and XPR technology, the ProteOn system can 
immobilize up to six separate ligands on a single sensor chip in six separate flow 
cells and then rotate the sensor chip 90 degrees to flow up to six separate analytes 
over the ligand surfaces (Figure 5.3). 
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Figure 5.3:ProteOn sensor chip 6 x 6 interaction array; allows for the detection of up to 36 
separate interactions on a single sensor chip (Bio-Rad, 2014). 
 
The unique feature of the ProteOn system allows for the detection of up to 36 
separate interactions on a single sensor chip and significantly increases the 
throughput of SPR biosensing. In a recent study, the ProteOn was used to 
immobilize 36 different ligands in a stepwise immobilization procedure designed for 
high-throughput epitope mapping as well as binding of antibody to antigen (Abdiche 
et al., 2011). The 6 x 6 interaction array of the ProteOn sensor chips also allows for 
in-line referencing, whereby data from unmodified spots in between the immobilized 
ligand spots on the sensor chip are used to subtract out artifacts such as noise and 
baseline drift. This ‘in-line’ referencing is superior to referencing with a separate flow 
channel and allows for the collection of high-quality SPR data at low signal-to-noise 
ratios, as is often required with small molecule analytes (Bio-Rad, 2014). 
 
5.1.3 Immobilization and Sensor Chips 
 
While biosensors do not require reactants to be labelled, one of the molecules must 
be immobilized onto a surface. As shown in Figure 5.4, direct coupling and capturing 
are the two general ways of immobilizing the ligand. Direct coupling [Figure 5.4(a)] 
has the advantage of creating a stable surface. Coupling through unique surface-
exposed residues such as an engineered cysteine is optimal (Myszka et al., 1996). 
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Random coupling procedures, such as involving primary amines, often introduce 
surface heterogeneity, which may complicate the analysis. Capturing methods 
[Figure 5.4(b)], such as antibodies or fusion tags, create homogeneous surfaces, but 
if the capturing step is not stable it may introduce a background surface decay which 
also complicates the analysis (Joss et al., 1998). Selecting the optimum 
immobilization method is specific per interaction and often involves a compromise 
between surface instability and introducing surface heterogeneity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4: Immobilization methods. (a) The direct coupling of the ligand (B) onto the 
biosensor chip. Commonly used coupling chemistries utilize amines, aldehydes or free thiols 
on the surface of the ligand. (b) An example of a capturing system. Here the ligand (B) is first 
captured onto the surface using another immobilized molecule (C). Common capturing 
methods include hexa-His and biotin/streptavidin. 
 
ProteOn sensor chips include more than just a gold layer; they are coated with a 
modified alginate polymer that provides a solution-like, biomimetic environment for 
ligand immobilization. The general-use ProteOn sensor chips (GLC, GLM, and GLH 
sensor chips) use carboxylic acid groups that react with surface-exposed amines on 
the ligand, tethering the ligand to the sensor chip in a random orientation. The 
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ProteOn NLC sensor chips are coated with NeutrAvidin for immobilization of 
biotinylated ligands, and the HTG and HTE sensor chips feature a Tris-NTA surface 
for immobilization of histidine-tagged proteins. 
 
5.1.3.1 General amine chips: GLC, GLM and GLH Chips 
 
Three ProteOn sensor chips are available for amine coupling. The GLC, GLM, and 
GLH chips allow compact, medium, and high ligand surface capacities, respectively. 
All three of these chips are functionalized with carboxylic acid groups that can be 
activated using EDAC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride) 
and sulfo-NHS (N-hydroxysulfosuccinimide) to react specifically with free surface 
amines of proteins.  
 
The GLC sensor chip is designed with a 2-D alginate layer for amine coupling of 
protein ligands at a compact (~ 6 kRU) surface capacity. The 2-D structure of the 
GLC chip helps mitigate mass transfer effects that are often observed with 3-D 
surfaces. The GLC chip is ideal for probing protein-protein interactions. 
 
The GLM sensor chip is coated with a thicker alginate polymer that displays a higher 
amount of carboxylic acid groups and is thus ideal for creating medium capacity (~ 
12 kRU) ligand surfaces via amine coupling. It can be used for both protein-protein 
interactions and protein-small molecule interactions. 
 
The GLH sensor chip is designed with a high density alginate polymer that contains 
an increased number of carboxylic acid groups to create a very high (>20 kRU) 
surface capacity. The GLH chip is ideal for probing protein-small molecule (<1kDa) 
interactions, as the high capacity surface gives an increased binding response. 
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5.1.3.2 Site-specific chips: NLC, HTG/HTE 
 
The NLC sensor chip is functionalized with NeutrAvidin bound to the alginate 
polymer and can capture biotinylated proteins, peptides, and nucleic acids. The NLC 
sensor chip is ideal for immobilizing ligands not suited to amine coupling, but 
requires that the ligand be modified with biotin prior to immobilization (Bio-Rad, 
2014). 
 
The HTG and HTE sensor chips feature a novel Tris-NTA complex for improved 
capturing of histidine-tagged proteins. The Tris-NTA complex contains three 
nitriloacetic acid (NTA) moieties for improved binding stability and increased binding 
selectivity to histidine-tagged proteins compared to the traditional mono-NTA, so that 
minimal ligand leaches off the surface and the sensorgram baseline remains stable. 
The Tris-NTA complex is attached to the alginate polymer matrix on the sensor chip 
and is activated using nickel (II) ions. The surface density of Tris-NTA complex is 
distinguished in the two different sensor chips, HTG for compact density and HTE for 
high density. The HTG chip is an ideal choice for protein-protein and protein-peptide 
interaction analysis, and the HTE sensor chip for protein–small molecule interaction 
analysis (Bio-Rad, 2014). 
 
5.1.4 Data analysis 
Using SPR, the ProteOn XPR36 system can provide a wide array of important 
information on biomolecular interactions such as the specificity, affinity, qualitative 
ranking, kinetics, and thermodynamics of binding. By fitting sensorgram data to a 
suitable binding model, kinetic parameters such as the association (ka) and 
dissociation (kd) rate constants and the affinity (KD) can be determined (Figure 5.5). 
Kinetic data are crucial for characterizing an interaction as they allow for a thorough 
understanding of the nuances of binding. 
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Figure 5.5: Elements of an optical biosensor analysis. (A) Analyte in solution binds to a 
target ligand immobilized on the sensor surface showing association and dissociation 
constants determined via (B) Biosensor output sensorgram. The response increases during 
the association phase as analyte flows across, and binds to, the immobilized ligand. A 
plateau in the response at the end of the association phase indicates that the system has 
reached equilibrium. The response decreases during the dissociation phase as the surface 
is washed with buffer and the analyte dissociates from the surface (Rich and Myszka, 2007). 
 
There are several different binding models to analyze sensorgram data: 
 
► Langmuir: Simple 1:1 bimolecular interaction 
 Simultaneous fitting of ka and kd 
 Fitting of dissociation (kd) only 
► Langmuir with drift: Simple 1:1 biomolecular interaction with a constant 
baseline drift taken into account 
► Langmuir with mass transport limitations: Simple 1:1 biomolecular interaction 
that takes into account the rate of diffusion of analyte from the bulk to the 
surface 
► Bivalent analyte: The analyte has two binding sites to one ligand. 
► Heterogeneous analyte: Two analytes compete for binding to the same ligand 
site 
► Heterogeneous ligand: One analyte binds to two separate ligand binding sites 
► Two-State Conformation: Accounts for a change in conformation of the 
binding complex that occurs after the analyte binds. In addition, it is possible 
to calculate the affinity value (KD) using equilibrium analysis, in which the 
equilibrium responses at different analyte concentrations are fitted to a simple 
saturation binding model. 
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The two-state conformational change model is of particular interest in binding of 
integrins to their ligands.  
 
The two-state conformation model accounts for the existence of two-conformations 
of the bound complex. This can happen if binding of the analyte to ligand triggers a 
change in conformation of the bound complex. The following equation describes the 
two-state conformation binding model: 
 
 
 
where AB is the first conformation of the bound complex and (AB)* is the second 
conformation of the bound complex. Once the complex AB forms it can either 
dissociate to unbound ligand (B) and free analyte (A) or change to the new 
conformation (AB)*. However, the complex (AB)* must return to the first complex AB 
before dissociating into unbound ligand and free analyte. The two-state conformation 
model is very useful for describing an allosteric binding effect where binding of 
analyte to ligand results in a conformational change. 
 
The application of SPR for studies of integrin ligand binding is tightly linked with the 
many recent advances made in understanding the structural biology of these 
receptors. The integrin α-I domains are the major ligand interaction site in the 
receptors, when present, and quantitative binding studies on the interaction between 
integrin and ligand have mainly been made with the isolated α-I domains. 
Considerable evidence now exists to suggest that ligand binding by the α-I domain is 
conformationally regulated, where the “open conformation” represents a ligand-
binding active form, while, by contrast, the alternate conformation, named “closed,” 
would not support ligand binding. Several strategies for controlling the conformation 
of the α-I domain by site-directed mutagenesis have been reported, and many of 
these studies have used SPR biosensor technology for studying changes in the 
affinity induced by the conformational regulation. It should be noted, however, that all 
wildtype α-I domains so far tested show binding detectable with SPR and the 
availability of high-affinity constructs is therefore not critically important  (Vorup-
Jensen, 2012). 
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5.2 Materials 
The BiotinTag™ Micro Biotinylation Kit, ExtrAvidin Peroxidase and TMB liquid 
substrate for membranes were purchased from Sigma-Aldrich (USA). GLC (#176-
5011) and NLC (#176-5021) chips and amine coupling kit (#176-2410) were 
obtained for use on a ProteOn XPR36 from Bio-Rad (UK). 
 
5.3 Methods 
5.3.1 Biotinylation of recombinant proteins 
For SPR, CD11b I-domain and GST proteins were biotinylated according to the 
BiotinTag Micro Biotinylation Kit manual. A biotinamidohexanoic acid 3-sulfo-N-
hydroxysuccinimide ester (BAC-SulfonoNHS) to protein ratio of 13:1 was used. This 
resulted in each protein molecule containing approximately 4-8 biotin tags.  
 
5.3.2 Dot Blot Assay 
Dot blot assays were performed to confirm biotinylation of recombinant CD11b I-
domain and GST proteins. Five hundred nanograms of each recombinant protein 
was spotted on activated PVDF. The spots were allowed to dry and the membrane 
blocked at room temperature for 1 hr in blocking buffer (20 mM Tris-HCl, pH 7.5, 150 
mM NaCl, 0.05% Tween-20 and 5% non-fat milk powder). ExtrAvidin peroxidase 
diluted 1:4000 in blocking buffer was added to the membrane and incubated at room 
temperature for 1 hr. Unbound ExtrAvidin peroxidase was removed by washing three 
times with TBS (20 mM Tris-HCl, pH 7.5, 150 mM NaCl and 0.05% Tween-20). The 
membrane was developed with TMB liquid substrate until dark blue spots appeared. 
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5.3.3 SPR using NLC Sensor Chip 
 
Surface plasmon resonance (SPR) spectroscopy was used to measure binding 
between CD11b I domain and recombinant CD23 at Rhodes University, South 
Africa. All experiments were performed at 25°C, using an NLC sensor chip, on a 
ProteOn XPR36 instrument. 
 
Equilibrium dissociation and kinetic constants were determined by SPR 
spectroscopy.  NLC Chips were used to immobilize biotin labelled CD11bα-I domain 
protein as the ligand at ~300 RU’s. The NLC chip does not require activation and 
immobilization was carried out at a flow rate of 30μL/min for 200 seconds from stock 
protein solutions of 2.5, 5 and 10µg/mL. 
 
Analytes included 16kDa derCD23, 25kDa WT CD23 and 25kDa mutant CD23 
(RKΔAA) at varying concentrations. Analytes were injected at 80μL/min for a 120 
second association phase followed by a 600 second dissociation phase using 
HEPES buffered saline [(HBS) 10mM HEPES, pH7.4, 150mM NaCl] for the ‘metal-
free’ running buffer or HBS containing 1mM MgCl2 and 2mM CaCl2 for the ‘metal’  
running buffer. Regeneration of the sensor chip surface was performed using two20 
second pulses of 40mM NaOH. Standard double reference data subtraction methods 
were used before analysis of kinetic binding. Curve fit and other data analyses were 
performed using BiaEvaluation Version 3.0.2 software (GE Healthcare, UK). 
 
5.3.4 SPR using GLC Sensor Chip 
A GLC sensor chip was also used to investigate the binding between CD11b I 
domain and recombinant CD23 via SPR.  
 
Amine coupling chips (GLC) require activation prior to ligand immobilization. A 1:1 
mix of EDAC (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride) and 
sulfo-NHS (N-hydroxysulfosuccinimide) was freshly prepared as the activation 
solution. Activation was performed, using the activation solution, followed by ligand 
immobilization (with protein concentrations of 2.5, 5 and 10µg/mL) at a flow rate of 
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30μL/min for 300 seconds for both activation and immobilization of CD11b I-domain 
and GST. Chip surfaces were deactivated using 1M ethanolamine-HCL at pH8.5 to 
block any remaining activated carboxyl groups. Deactivation was performed in the 
vertical direction, the same direction as activation and ligand immobilization 
injections.  
 
Injection of analytes and regeneration was performed as for the NLC chip (Section 
5.3.3) with modifications to flow rate (50-100μL/min) and association time (60-150s). 
 
 
5.4 Results and Discussion 
5.4.1 Dot Blot analysis of biotinylated proteins 
A dot blot was performed to show that biotinylation was successful (Figure 5.6). It 
was evident that the dots for CD11b I-domain and GST varied in intensity. This was 
initially unexpected as the same concentration of each protein (500ng) was applied 
to the PVDF membrane. The biotin derivative BAC was used for biotinylation of 
proteins via an amine reaction, thus the level of biotinylation will vary from one 
protein to another, due to different numbers of lysine residues available for biotin 
modification. A positive control should have been used for comparative purposes; 
however, the development of blue spots for CD11b I-domain and GST indicated 
successful biotinylation of the recombinant proteins.  
 
 
 
 
 
 
 
 
Figure 5.6: Dot blot showing the biotinylation of CD11b I-domain and GST. Five hundred 
nanograms of each protein were applied to the PVDF membrane. 
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It was important that biotinylation was successful as the biotin tag was used for 
immobilization of CD11b I-domain and GST ligands to the NLC sensor chip for SPR 
analysis.  
 
5.4.2 Analysis of Surface Plasmon Resonance Spectroscopy 
 
Equilibrium dissociation and kinetic constants were determined by surface plasmon 
resonance spectroscopy on a ProteOn XPR36. 
 
5.4.2.1 SPR spectroscopy using NLC sensor chip 
 
A number of studies have shown that CD23 binds to the β2-integrins, (Lecoanet-
Henchoz et al., 1995, Bonnefoy et al., 1996) and more recently, CD23 binds 
specifically to the α chain CD11b/c I-domain (Daniels, 2010). However, kinetic 
analysis for this interaction requires further investigation. 
 
Using a ProteOn XPR36 instrument, three kinetic experiments were performed as 
described in section 5.3.3, with CD11b I-domain as the ligand and 16kDa derCD23, 
25kDa WT CD23 and 25kDa mutant CD23 (RKΔAA) as analytes. A global fitting 
procedure was used to determine rate constants after standard double referencing 
was performed. Data were fit to a two-state conformational change model in 
accordance with the conformational changes associated with binding of integrins to 
their ligands (Lee et al., 1995, Shimoaka et al., 2002 and Vorup-Jensen, 2012). 
 
The data obtained in this section were of particular interest as the interaction 
between CD11b I-domain and CD23 has not been fully characterised. Sensorgrams 
and fitted binding curves (Figures 5.7 and 5.8) for the binding of CD11b I-domain to 
16kDa derCD23, 25kDa WT CD23 and 25kDa mutant CD23 (RKΔAA) were obtained 
and analysed using BIAevaluation v3.0.2. 
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Figure 5.7:(A) Sensorgrams depicting the measurement of the dissociation constant (KD) for 
the binding between the CD11b α-I domain and WT sCD23 on NLC chip. Analyte was 
injected for 120s and dissociation monitored for 600s at 80 µL/min, 25°C, in HBS ‘metals’ 
running buffer.  Data were fitted to a two-state conformational change model with 
BIAevaluation v3.0.2 after standard double referencing. Inset shows association and 
dissociation rate constants. (B) Relative residual plot showing the accuracy of fit (χ2 ~5.54). 
 
 
Integrin interactions with ligands requires a conformational change in the integrin I 
domain from a closed low affinity state to an open high affinity state (Xiong et al., 
2013).  The SPR data of the CD11b α-I domain interaction with CD23 (Figures 5.7 
and 5.8) fits this model, showing an initial fast association with the low affinity state 
of CD11b, followed by a slow off-rate in the high affinity state.   
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The kinetics of the interaction between β2 integrin I domains and their ligands have, 
in general, showed sufficiently fast kinetics, permitting determination of the 
dissociation constant (KD) by steady-state equilibrium. Vorup-Jensen (2012) 
performed SPR spectroscopy using CD11c I-domains and the ligand iC3b. The KD 
value obtained for the interaction of high-affinity CD11c I-domain and iC3b was 3.1 
μM where the αX I domain was applied to the iC3b-coupled surface and a control 
surface in ten concentrations ranging from278 nM to 10.6 mM. Results were fitted 
using a 1:1 binding model and analysed using the method described by Svitel et al., 
(2003). Jin et al., (2006) performed SPR spectroscopy using ICAM-1 and various 
CD11a I-domains mutationally locked in low, intermediate or high affinity 
conformations. By fitting the 1:1 Langmuir binding model to sensorgrams, the KD 
values determined by Jin et al. (2006), were; 1500μM for the low (wild-type) affinity, 
3μM for the intermediate affinity and 0.15μM for the high affinity conformation. The 
association rate constants (ka) were forty-fold higher for the intermediate and high 
affinity (~115 000M-1s-1) than for the low affinity conformation (3000M-1s-1). The 
dissociation rate constants (kd) for the low, intermediate and high affinity 
conformations were 4.6s-1, 0.43s-1 and 0.014s-1, respectively.  
 
Data were fit to a two-state conformational change model in accordance with the 
conformational changes associated with binding of integrins to their ligands (Lee et 
al., 1995, Shimoaka et al., 2002 and Vorup-Jensen, 2012).The binding constants 
(Figure 5.7 inset) were obtained for the interaction of CD11b I-domain and CD23 
over a suitable concentration range (37-3000nM). The initial low affinity association 
rate (ka1) is fast (1.1x105M-1s-1) followed by a slow dissociation in the high affinity 
state (kd2 ~4.9x10-5s-1) indicating a high affinity between CD11b I-domain and CD23. 
The initial association rate, ka1, is highly comparable to the ka determined by Jin et 
al., (2006) of 1.15 x105 s-1. However, both kd1 and kd2 were substantially slower than 
the kd values obtained for either low, intermediate or high affinity CD11a I-domain 
binding to iCAM-1. This disparity in dissociation constants was in the order of several 
magnitudes; (kd1) 4.6 x10-3s-1, (kd2) 4.9 x10-5 s-1 as opposed to 4.6, 0.43 and 0.014s-1 
for ICAM-1 (Jin et al., 2006). KD was calculated (kd1/ka1) to be 41.8nM for the 
interaction between CD11b I-domain and CD23, compared to 150nM and 3100nM 
for ICAM-1 and iC3b, respectively (Vorup-Jensen, 2012 and Jin et al., 2006). These 
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parameters suggest that CD11b I-domain may bind CD23 with a higher affinity and 
may form more stable complexes with CD23 than both ICAM-1 and iC3b. 
 
 
 
Figure 5.8: (A) Sensorgrams depicting the measurement of the dissociation constant (KD) for 
the binding between the CD11b α-I domain and CD23, derCD23, and mutant CD23 on NLC 
chip. Analyte was injected for 120s and dissociation monitored for 600s at 80 µL/min, 25°C, 
in HBS ‘metals’ running buffer. Data were fitted to a two-state conformational change model 
with BIAevaluation v3.0.2 after standard double referencing. (B) Relative residual plot 
showing the accuracy of fit (χ2 ~0.42 – 3.44). 
 
Table 5.1: Binding constants for CD11b α-I domain interaction with CD23 using NLC 
chip. Data were fitted using a two-state conformational change model with 
BIAevaluation 3.0.2. 
Analyte ka1(M-1.s-1) kd1(s-1) ka2(s-1) kd2(s-1) Chi2 
CD23 2.39 x104 1.41 x10-3 1.03 x10-2 5.60 x10-5 3.44 
CD23 RKΔAA 1.09x105 1.20 x10-3 5.89 x10-3 8.44 x10-4 0.42 
derCD23 2.41x103 2.30 x10-4 1.14 x10-5 1.01 x10-5 2.32 
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Large residuals were obtained during the association of CD11b I-domain and CD23 
(Figure 5.7 B and 5.8 B). This suggests that there is a large difference between the 
experimental data and the fitted data. The residual values obtained for dissociation 
were more acceptable, only deviating by ~2RU’s. Thus, the dissociation rate 
constants obtained from the experiment can be deemed accurate. When the 
deviations are seen as a definite shape it may be an indication that the interaction 
model is, to a greater or lesser extent, unsuitable for the interaction. However, the 
Chi2 values (Table 5.1) indicate a sufficiently good fit of the model to the 
experimental data. Chi2 is an indicator of how closely the fitted curves agree with the 
experimental data. It is a measure of the average squared residual. For good data 
fitting, the Chi2 should be in the same order of magnitude as the instrument noise 
level, usually <2RU.   
 
Binding analysis of a single concentration of three analytes; CD23, derCD23 and 
mCD23, revealed that mutation of the RKC motif in CD23 to AAC causes a faster 
association rate for the low affinity state, but dissociation rates of the complex 
appear unaffected. The rate of high affinity reversion (kd2) is faster for the mutant 
which, together with a faster ka1, suggests that the mutant binds equally well to the 
low affinity state of CD11b I-domain (Figure 5.8, Table 5.1).Calculation of the KD for 
the interaction between CD11b I-domain and WT CD23 or mCD23 yields 59nM and 
11nM, respectively. This was unexpected as ELISA-based peptide analyses by 
Pereira (2012) infer that the native sCD23 and a RKC peptide were able to bind to 
the integrin α I-domain, whereas the mutant sCD23 and the corresponding synthetic 
AAC peptide failed to bind. Pereira (2012) also analysed the interaction via flow 
cytometry, using differentiated U937 cells, which yielded similar results. ELISA 
analyses for the sCD23-CD11b I-domain interaction showed a KD of 0.36 ± 0.14 μM 
whereas the RKC-CD11b I-domain interaction yielded a KD of 1.75 ± 0.58 μM. 
Peptide inhibitory analysis, analysed via ELISA and flow cytometry, indicated that the 
RKC motif on sCD23 is a prerequisite for ligand binding of the CD11b I-domain. 
However, SPR analysis in this case reveals that mCD23 does indeed bind CD11b I-
domain and with a slightly higher affinity than the wild-type, especially noted as a 
faster association rate for the low affinity state. Although SPR spectroscopy is known 
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to be more sensitive than ELISA analysis, the discrepancy between these results 
requires further investigation.    
 
From table 5.1, SPR analysis of the interaction between CD11b I-domain and 
derCD23 revealed a moderately slower association and slower dissociation rate for 
the low affinity state. However, the rate of high affinity association was remarkably 
slower than for the 25kDa CD23. Calculation of the KD shows a lower affinity for the 
interaction between CD11b I-domain and derCD23 (95nM) than for 25kDa CD23 
(59nM). 
 
Data analysis proved to be problematic for Vorup-Jensen, (2012), because there 
was disparity in equilibrium response (Req) between incremental differences in ligand 
concentration while studying the interaction of the αX I domain with iC3b. This would 
not be the case if the I domain-iC3b was a 1:1 interaction with a KD of 3 μM, since all 
of the analyte concentrations were higher than KD. The incremental difference 
between concentrations of CD23, in this case, also showed disparity, especially at 
the higher concentration limit. For Vorup-Jensen, an even more disturbing finding 
came from calculation of the stoichiometry. With the Mr of the αXI domain at 23400 
and the Mr of iC3b at 180000, stoichiometry became 5.6, i.e., suggesting that 
approximately six binding sites for I domains may exist within the iC3b molecule. 
This observation clearly suggests that the interaction between the I domain and 
theiC3b ligand is not a simple 1:1 interaction. This led to complexities when 
analysing heterogenous binding sites using simple 1:1 models. Based on earlier 
observations from the binding between I domain and fibrinogen, one approach is the 
application of the algorithms developed by Schuck and colleagues (2007).  
 
Schuck and colleagues (2007) developed a mathematical algorithm for obtaining 
meaningful information from binding experiments involving ligand-coated surfaces 
with a heterogeneous composition of analyte-binding sites. An important feature is 
that the algorithm does not require an ad hoc assumption about a specific number of 
discrete sites (e.g., two as in the case of the BIAevaluation software), and instead is 
based only on the weaker assumption that there could be heterogeneity of sites with 
rate and affinity constants in an operator-specified range. The exact methodology of 
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this algorithm and the implementation of MatLab code for analysis of the binding 
data are complex, but in principle, REq plotted as a function of the analyte 
concentration portrays information on the composition of binding sites on a surface. 
However, a far more rigorous analysis of binding site heterogeneity can be 
accomplished by considering the kinetics of the interaction. By providing appropriate 
information on the concentrations of analyte applied to the surface, contact time, and 
the post-injection time interval required to be analyzed, the experimental data are 
characterized. For the analysis, the range for determination of the kinetic 
parameters, i.e., kon and koff, must also be specified. After specifying the number of 
grid-points, related to the kon and koff rates, a two-dimensional grid is generated, with 
each grid point corresponding to a type of interaction specified by koff and KD. 
Following analysis of the supplied data, the algorithm for each grid point associates a 
number (in RU) indicating the abundance of interactions at binding saturation with 
kinetic parameters corresponding to the grid point. The number of binding sites 
within a ligand molecule can then be calculated; a value similar to RMax, and hence 
the total number of binding sites with a single ligand molecule can be calculated as 
the sum of the abundances of all grid points (Svitel et al., 2003, 2007 and Vorup-
Jensen, 2012). 
 
Vorup-Jensen (2012) therefore concluded that heterogeneity in the interaction 
between surface exposed binding sites can lead to ‘masking’ of low-affinity 
interactions. Although the biological implication of the heterogeneous interactions 
between the αX I domain and ligands is still poorly understood, recent evidence 
suggests that a similar phenomenon is the case for αM I domain, while the αL I 
domain binds ICAM-1 in a relatively homogeneous way. These findings clearly 
suggest that care must be taken in the analysis of I-domain:ligand interactions, with 
as few as possible assumptions limiting the outcome of the analysis (Vorup-Jensen 
et al., 2005, 2008, 2012). 
 
In this experiment, fibrinogen was used as a positive control as it is known to bind 
the CD11b I-domain (Nham, 1999).  However, it was found to bind the NLC chip 
non-specifically and subsequent regeneration steps were inefficient in returning the 
response to baseline levels. Consequently, fibrinogen was eliminated from further 
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experiments which unfortunately also eliminated the positive control component for 
these experiments.  
 
According to manufacturer’s instructions, the NLC chips do not require activation, the 
biotin-tagged proteins are simply immobilised via interaction with NeutrAvidin and 
deactivation with biotin is optional. In this case, deactivation of the chip surface with 
biotin was not performed.  Deactivation may have diminished the non-specific 
binding of fibrinogen to the chip surface thus allowing validation as a positive control 
in SPR spectroscopy. Another important consideration when using NLC chips is 
biotinylation (Ritzefeld and Sewald, 2011). It is important to assess the result of 
biotinylation after ligand preparation. If the biotinylation step was not successful, 
ligand capture would not be observed on NLC chips. In this case the dot blot assay 
(Section 5.4.1) confirmed biotinylation was successful. If excess biotin is not 
removed properly from the ligand sample, it will occupy the available binding sites on 
the chip surface and result in low binding levels, typically of a few tens of RU. This 
was mitigated by using gel filtration supplied with the biotinylation kit; however, the 
biotin content was not determined prior to SPR spectroscopy. The most important 
consideration is over-biotinylation. If the ligand is biotinylated and captured on the 
chip surface but does not show a binding response with the analyte, over-
biotinylation may have occurred, and Lys residues important for binding may be 
blocked. To avoid this, it is recommended to prepare the ligand in a stoichiometry of 
1:1 (one biotin molecule per ligand molecule). This also prevents cross-linking of the 
ligand (Ritzefeld and Sewald, 2011). Alternatively, the biotinylation procedure can be 
carried out in a low pH buffer (50mM acetate, pH5.5) to favour the selective 
biotinylation of alpha-amino groups, which leaves the lysine residues unblocked (Bio-
Rad, 2014).  
 
5.4.2.2 SPR spectroscopy using GLC sensor chip 
 
The Bio-Rad GLC sensor chips are used for the general amine coupling of ligands to 
the chip surface. The GLC chips were used subsequently to the NLC chips in this 
experiment due to non-specific binding to the NeutrAvidin chip surface. The 
immobilization of ligand to the GLC chip requires activation of the chip surface prior 
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to immobilization and thereafter deactivation of the unoccupied spaces by 
ethanolamine. This reduces non-specific binding to the GLC chip surface.   
 
Immobilization levels using the GLC chip were much higher than for the NLC chip 
(Table 5.2). This may have been due to the biotinylation procedure limiting 
immobilization to the NLC chip, or the ease with which the ligands immobilized via 
their amine groups to the carboxylic acid groups on the GLC chip surface. According 
to Bio-Rad, the approximate ligand immobilization capacity of the NLC and GLC 
chips is ~2kRU and ~8kRU, respectively, which may have also impacted the 
difference observed in ligand immobilization levels.    
 
Table 5.2: Ligand immobilization levels for the NLC and GLC sensor chips.  
Ligand * NLC Chip GLC Chip 
CD11 (low) ~325 RU ~700 RU 
CD11 (mid) ~440 RU ~1300 RU 
CD11 (high) - ~2100 RU 
GST (low) ~240 RU ~250 RU 
GST (mid) ~220 RU ~2000 RU 
* The low, mid or high denotation is according to the target level of immobilization due to the 
stock concentrations prepared; viz. 2.5μg/mL, 5μg/mL and 10μg/mL, respectively. 
 
Another immobilization factor also gave rise to concern; the difference in 
immobilization levels between GST low concentration (~250 RU) and mid 
concentration (~2000 RU) for the GLC chip. This may have been caused by the 
propensity of GST to form dimers and even oligomers (Harper and Speicher, 2011).  
 
Following immobilization, the binding of CD11b I-domain to 25kDA wild type CD23, 
mCD23 (RKΔAA) and derCD23 in the presence or absence of metals, was 
investigated using a GLC chip and SPR spectroscopy. Sensorgrams were analysed 
and data were fit locally to the 1:1 Langmuir model (Figures 5.9, 5.10 and 5.11). 
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Figure 5.9: (A) Sensorgrams depicting the measurement of the dissociation constant (KD) for 
the binding between the CD11b α-I domain and 25kDa CD23 on GLC chip. Analyte was 
injected for 120s and dissociation monitored for 600s at 100 µL/min, 25°C, in HBS ‘metals’ 
running buffer. Data were fitted to the 1:1 Langmuir model with BIAevaluation v3.0.2. (B) 
Relative residual plot showing the accuracy of fit (X2~1.34). 
 
 
Figure 5.10: (A) Sensorgrams depicting the measurement of the dissociation constant (KD) 
for the binding between the CD11b α-I domain and mCD23 (RKΔAA) on GLC chip. Analyte 
was injected for 120s and dissociation monitored for 600s at 100 µL/min, 25°C, in HBS 
‘metals’ running buffer. Data were fitted to the 1:1 Langmuir model with BIAevaluation 
v3.0.2. (B) Relative residual plot showing the accuracy of fit (X2~1.43). 
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Figure 5.11: (A) Sensorgrams depicting the measurement of the dissociation constant (KD) 
for the binding between the CD11b α-I domain and 25kDa CD23 with metal-free buffer on 
GLC chip. Analyte was injected for 120s and dissociation monitored for 600s at 100 µL/min, 
25°C, in HBS ‘metal-free’ running buffer. Data were fitted to the 1:1 Langmuir model with 
BIAevaluation v3.0.2. (B) Relative residual plot showing the accuracy of fit (X2~1.94). 
 
As previously stated, the Chi2 value is an indication of how closely the fitted curves 
agree with the experimental data. From previous data fitting using the two-state 
conformational change model, acceptably low Chi2 values were obtained, however, 
the interaction between CD23 and CD11b I-domain was subsequently fitted to the 
1:1 Langmuir model with even lower Chi2 values, suggesting that this model may 
more accurately characterize the binding interaction.  
 
The local fitting of the 1:1 Langmuir model determined the binding constants (Table 
5.3) for the interaction of CD11b I-domain to CD23 and mCD23 with GST as a 
control. Various experimental parameters were altered in order to optimise the 
sensorgrams obtained; these included flow rate, association time and analyte 
concentration (Appendix B).  
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Table 5.3: Binding constants for CD11b α-I domain interaction with CD23 using GLC 
chip. Data were fitted using the 1:1 Langmuir model with BIAevaluation 3.0.2 
Analyte ka (M-1.s-1) SE (ka) kd (s-1) SE (kd) KD (M) Chi2 
CD23 (Wild type) 1.26 x104 157.53 6.20 x10-4 2.07 x10-5 5.16 x10-8 1.34 
mCD23 (RKΔAA) 1.00 x104 254 3.06 x10-4 1.30 x10-5 3.19 x10-8 1.43 
CD23 metal free 3.83 x103 175 2.05 x10-4 1.27 x10-5 7.10 x10-8 1.94 
 
* SE values calculated using single data set and is an estimate of how sensitive the fitting is 
to changes in the parameter 
 
The data shown in Table 5.3 were obtained from fitting sensorgrams from an 
experimental response where the flow rate was 100μL/min for an association of 120s 
and dissociation of 600s. KD values obtained for the interaction between CD11b I-
domain and mCD23, as well as wild type CD23 in the presence of metals (Mg2+ and 
Ca2+) and without metals, were very similar (31.9nM, 51.6nM and 71.0nM, 
respectively). However, the interaction with CD23 in the absence of metals shows a 
much lower ka value than forCD23 with metals or the mutant CD23. A lower ka 
indicates a slower association between CD23 and CD11b I-domain in the absence of 
metals. This is as expected as metal divalent ions are involved in conformational 
regulation of both CD23 and CD11 in binding to ligands (Wurzburg et al., 2006, 
Springer, 1997). The interaction of CD11b I-domain and CD23 show much lower KD 
values than for the interaction with iC3b determined by Vorup-Jensen, (2012), 52nM 
compared to 3100nM. It is also lower than for the binding of CD11a I-domain to 
iCAM-1 (150nM for the high affinity I-domain) observed by Jin et al., (2006). The 
immense disparity in affinities gives rise to concern regarding the significance of data 
fitting for integrins binding to their ligands.  
 
When comparing values for ka and kd between chip surfaces (Tables 5.1 and 5.3), 
the NLC chip shows slightly faster ka and kd values than for the GLC chip, especially 
for mutant CD23. This may be due to the ligand immobilization techniques affecting 
the conformation and/or binding capacity of the CD11b I-domain.  
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Nevertheless, the Chi2 values were acceptably low (<2) for each fit and the residuals 
show excellent fitting for dissociation, though association still shows scattered 
residuals. As seen in figures 5.8, 5.9, 5.10 and 5.11, a number of sensorgrams 
depict a ‘sigmoidal’ or ‘biphasic’ shaped association curve. This phenomenon directly 
influenced the Chi2 values and residual plots as the experimental data deviated from 
the fitted mathematical model. The shape of the association curve was unexpected 
and may have been the result of a biphasic interaction. Edkins et al., (2012), indicate 
that αVβ3 and αVβ5 integrins bind RKC peptides with basic target elements with 
biphasic kinetics in a cation-independent manner. Hibbert et al., (2005), observed 
cooperativity and biphasicity in the binding of CD23 and IgE fragment Cε2-4, which 
corresponds with the reported biphasic kinetics of IgE binding to monomers and 
trimers of membrane CD23 at the cell surface (Lettelier et al., 1989 and Dierks et al., 
2003). Hibbert et al. (2005) determined, via sedimentation equilibrium, that CD23 is 
monomeric at the concentrations used in their SPR experiment (comparable to this 
experiment), and thus the IgE Fc must stabilize their oligomerization. Another 
example of biphasicity is provided by Toth et al., (2000). They show biphasic 
association curves for the interaction between the catalytic subunit of type 1 protein 
phosphatase (PP1c) and the N-terminal half of myosin phosphatase target subunit 1 
(MYPT1). The curves are sigmoidal in shape with fast and slow components which 
they attribute to the conformational change in PP1 which facilitates interactions with 
other regions of MYPT1. Both of these instances (oligomerization or conformational 
change) of biphasicity may account for the sigmoidal shape of the association curve 
between CD23 and CD11b I-domain. However, it may also be as a result of 
concentration effect, in that excess analyte re-binds to adjacent ligand during the 
association phase. This association/dissociation rebinding effect may occur when 
there is a higher concentration of ligand immobilised than is required for kinetic 
analyses, which may well have been the case for the amine-coupled CD11b I-
domain to the GLC sensor chip. In order to mitigate this effect, a slower flow rate 
was used as well as a shorter association time. Sensorgrams (Appendix B) were 
fitted using the 1:1 Langmuir model and were analysed to determine if this corrected 
the appearance of the association curve. 
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Table 5.4: Binding constants for CD11b α-I domain or GST interaction with CD23 using GLC 
chip during experimental optimization. Association time (60s) and flow rate as indicated. 
Data were fitted using the 1:1 Langmuir model with BIAevaluation 3.0.2 
Analyte Flow 
Rate 
Ligand ka (M-1s-1) kd (s-1) KD (M) Chi2 
50 μL/min CD11 (mid) 1.70 x104 8.15 x10-4 7.25 x10-8 1.65 
100 μL/min CD11 (mid) 2.39 x103 9.91 x10-4 6.38 x10-7 2.4 
50 μL/min CD11 (high) 2.06 x104 9.03 x10-4 5.39 x10-8 1.45 
100 μL/min CD11 (high) 5.48 x103 5.88 x10-4 1.24 x10-7 3.02 
50 μL/min GST (high) 1.53 x104 1.01 x10-3 9.80 x10-8 1.24 
100 μL/min GST (high) 3.21 x104 1.11 x10-3 3.90 x10-8 2.19 
 
The alteration of the association time served to shorten the sensorgram, slightly 
masking the sigmoidal shape of the association curve, especially at the highest 
concentration of analyte, however, the lower concentrations still exhibit this errant 
curve. Interestingly, the lower flow rate (50μL/min) dramatically improved the fit of 
the model to the experimental data, as seen by the shape of the fit as well as the 
Chi2 values (Table 5.4). To our dismay, the GST fusion tag, which was immobilised 
as a control, also showed binding to CD23. Although the ka values are lower and the 
kd values faster than for CD23, indicating lower affinity for GST binding to CD23, any 
interaction may be due to the extreme over-immobilization of GST to the GLC chip 
surface. This is supported by a lack of CD23 binding to GST at the low 
immobilisation level of GST.  Higher flow rates, in conjunction with lower 
immobilization levels, are recommended for kinetic studies in order to limit mass-
transfer effects or steric hindrance (BIAevaluation handbook, 1997).  
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6 CONCLUSIONS AND FUTURE STUDIES 
 
 
The first purpose of this study was to express and purify recombinant forms of the 
CD11bI-domain, CD18 I-Like domain as well as sCD23 in its wild type and mutant 
forms. This was successfully achieved by making use of two types of bacterial 
expression systems whereby the pET vector system was used to express the 
sCD23and the pGEX-GST fusion system was employed to express the I-domain of 
CD11b. The GST fusion system was similarly employed for the expression of CD18 
I-like domain based on structural homology with the CD11b I-domain. The CD18 I-
like domain was synthesized following codon optimization and successfully cloned 
(Figure 3.6) using a pET42b vector which encodes a GST fusion tag. Site-directed 
mutagenesis proved an invaluable technique for carrying out the mutation of the 
serine residue within the MIDAS site of the CD18 I-like domain. The serine was 
mutated to proline, based on mutations within LAD patients, and alanine to assess 
the effect of a non-polar mutation within the ligand binding site. Expression plasmids 
containing the desired mutations were successfully confirmed by DNA sequencing.  
 
Biologically active sCD23 has previously been successfully produced (Hibbert et al., 
2005; Wurzburg et al., 2006). Hibbert et al. (2005) obtained soluble CD23 from 
inclusion bodies produced in E. coli. They achieved this by using a refolding method 
developed for the production of biologically active papain (Taylor et al., 1992). 
Wurzburg et al. (2006) produced soluble CD23 in insect cells with the Bacculovirus 
system. Hibbert et al. (2005) and Wurzburg et al. (2006) respectively determined the 
three dimensional structure of 16 kDa CD23 through NMR and the 25 kDa CD23 
with X-ray crystallography. Although a three dimensional structure is unavailable for 
the mCD23 (RKΔAA) produced in this study, wild type CD23 produced according to 
Daniels et al. (2005) has been shown to bind IgE and CD21 (Bowles et al., 2011), 
inferring its biological activity and hence structural integrity. 
 
The expression, refolding and purification of recombinant sCD23 from E. coli has 
become a routine procedure in the FcReceptor Research Group of the Nelson 
Mandela Metropolitan University (Daniels, 2003; Askew, 2005; Daniels, 2010; 
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Bowles, 2010; Pereira, 2012). In this study the same procedure was successfully 
used to produce soluble 25 kDa mCD23 (RKΔAA). Recombinant CD23 expressed by 
E. coliBL21 (DE3) resulted in the formation of inclusion bodies (Figure 4.6). The 
inclusion bodies from four litres of culture were successfully isolated (Figure 4.7), 
refolded (Figure 4.8) and purified by size exclusion chromatography (Figure 4.9). 
Successful production of recombinant CD23 meant that it could be used in 
subsequent binding studies.  
 
The purification of the CD11b I-domain protein was relatively simple. The glutathione 
S-transferase (GST) Gene Fusion System (which is based on inducible, high-level 
expression of genes or gene fragments as fusions with S. japonicum GST) proved a 
versatile system for the expression and purification of the CD11b I-domain. 
Expression in E. coli yielded a soluble fusion protein which accumulated within the 
cell‘s cytoplasm. The GST fusion proteins were successfully purified from bacterial 
lysates by affinity chromatography using immobilized glutathione, whereby the GST 
fusion proteins were captured by the affinity medium and impurities were removed by 
repeated washing. Purified fusion proteins were eluted effectively under mild, non-
denaturing conditions using reduced glutathione and analysed via SDS-PAGE 
(Figure 4.2). Successful production of recombinant CD11b I-domain meant that it 
could be used for subsequent binding studies to analyse its interaction with CD23.  
 
The purification of CD18 I-like domain was not as simple. The recombinant proteins 
were clearly upregulated after induction with IPTG (Figure 4.1), but it is unclear 
whether they remained in the soluble or insoluble fraction after sonication and 
centrifugation (Figure 4.4). The cell lysate was used for affinity chromatography 
using immobilized glutathione, but when analysed via SDS-PAGE it appears only 
GST fusion tag eluted. This may have been due to truncation of the protein during 
translation, proteolytic degradation or as a result of the recombinant protein being 
insoluble and present as inclusion bodies. Western blot analysis (Figure 4.5) 
revealed a band of the correct size indicating that at least a very small percentage of 
recombinant CD18 I-like domain may be soluble and purified via GST affinity 
chromatography. Premature termination of translation is unlikely owing to the 
optimisation procedure carried out by GenScript, where translation performance 
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efficiency was enhanced. Proteolytic cleavage may still be possible even though a 
general protease inhibitor cocktail was used. Perhaps an E.coli specific protease 
inhibitor cocktail could be employed in future studies regarding purification of 
recombinant proteins.  
 
In order to obtain soluble CD18 I-like domain, future studies could include a more 
comprehensive set of modifications to the expression procedure, such as lower 
temperature, lower concentration of IPTG, different expression hosts, inoculum 
densities and stress treatments. Alternatively, which may have more success, is 
expression of high quantities of CD18 ILD as inclusion bodies. Cierniewska-Cieslak 
et al., (2002) describe the production of two recombinant β3 subunits based on the 
homology to the CD11 I-domain. The coding sequences were cloned into a pRSETa 
(Invitrogen) vector for expression as an N-terminal His-tagged fusion protein. 
Inclusion bodies were prepared, dissolved in 6 M urea, and separated by 
chromatography. Refolding was performed by dialysis of dilute protein and repeated 
dilution followed by ultrafiltration. For future studies, this approach may have many 
advantages, such as eliminating optimisation of expression therefore saving time 
and lab consumables. A notable advantage is the replacement of the large GST-
fusion tag with the much smaller His-tag which may reduce steric hindrance effects 
incurred by GST. Purification is just as easy for His-tagged proteins as GST-tagged 
proteins. When using the His-tag, the metal binding domain of the His-fusion peptide 
allows simple purification of recombinant proteins by immobilized metal affinity 
chromatography (IMAC). The enterokinase cleavage recognition site in the fusion 
peptide located between the metal binding domain and the recombinant protein also 
allows for subsequent removal of this N-terminal fusion peptide from the purified 
recombinant protein, which may have immense advantages during SPR 
spectroscopy.  
 
The second purpose of this study was to analyse the interaction between CD23 and 
β2 integrins. The CD11b I-domain was successfully expressed and purified and used 
for this purpose, together with 25kDa wild type CD23, mCD23 (RKΔAA) and 
derCD23. The application of SPR for studies of integrin ligand binding is tightly linked 
with the many recent advances made in understanding the structural biology of these 
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receptors. The integrin I domains are the major ligand interaction site in the 
receptors, which carry them, and quantitative binding studies on the interaction 
between integrin and ligand have mainly been made with the isolated I domains 
(Vorup-Jensen, 2012). 
 
Using a ProteOn XPR36, two chip surfaces were explored; NLC for biotinylated 
ligand immobilization and GLC for general amine coupling to the chip surface. The 
NLC chip was used first, but fibrinogen, used as a positive control, caused non-
specific binding and regeneration could not return signal to baseline. The GLC chip 
was then utilized, however, the amine coupling procedure was far more efficient than 
expected, which resulted in ‘over-immobilization’ of the chip surface (Table 5.2). 
Lower ligand densities are recommended for kinetic studies.  
 
The sensorgrams obtained were fitted locally using BIAevaluation 3.0.2 using either 
a two-state conformational change model or 1:1 Langmuir binding model.  
 
For the NLC chip, sensorgrams were fitted using the two-state conformational 
change model based on the knowledge that integrin interactions with ligands require 
a conformational change in the integrin I domain from a closed low affinity state to an 
open high affinity state (Xiong et al., 2013).  The SPR data of the CD11b α-I domain 
interaction with CD23 (Figure 5.7) fits this model, showing an initial fast association 
with the low affinity state of CD11b, followed by a slow off-rate in the high affinity 
state.  Mutation of the RKC motif in CD23 to AAC causes a faster association rate for 
the low affinity state, but dissociation rates of the complex appear unaffected. The 
rate of high affinity reversion (kd2) is faster for the mutant which, together with a 
faster ka1, suggests that the mutant binds better to the low affinity state of CD11b I-
domain (Figure 5.8, Table 5.1). 
 
For the GLC chip, sensorgrams were fitted to the 1:1 Langmuir binding model. This 
model shows excellent fitting to experimental data, especially for dissociation, as 
seen by the Chi2 values in Table 5.3. KD values obtained for the interaction between 
CD11b I-domain and mCD23, as well as wild type CD23 in the presence of metals 
(Mg2+ and Ca2+) and without metals, were very similar (31.9 nM, 51.6 nM and 71.0 
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nM). However, the interaction with CD23 in the absence of metals shows a much 
lower ka value than for CD23 with metals or the mutant CD23. A lower ka indicates a 
slower association between CD23 and CD11b I-domain in the absence of metals. 
This is as expected as metal divalent ions are involved in conformational regulation 
of both CD23 and CD11 in binding to ligands (Wurzburg et al., 2006, Springer, 
1997).The mCD23 does show a slower dissociation than wild type (3x10-4 as 
opposed to 6x10-4 s-1) which is contrary to the results from the NLC chip, where 
dissociation of the complex was unaffected while association for the low affinity state 
was faster for the mutant. 
 
The association curves obtained from these experiments gave rise to concern due to 
their atypical ‘sigmoidal’ shape. Biphasicity was explored as an explanation due to 
the observed cooperativity and biphasicity in the binding of CD23 and IgE fragment 
Cε2-4, which corresponds with the reported biphasic kinetics of IgE binding to 
monomers and trimers of membrane CD23 at the cell surface (Lettelier et al., 1989 
and Dierks et al., 2003). Another explanation was the conformational changes 
associated with the β2 integrins as well as the extremely high ligand concentration 
immobilized on the chip surface. These concerns, together with the observed binding 
between CD23 and GST lead to a few recommendations for future SPR studies: 
 
 One of the first recommendations for SPR optimisation is switching the 
analyte and ligand around. However, the CD11c I-domain has previously 
been found to bind non-specifically to the chip surface when used as analyte 
(Daniels, 2010) 
 Cleavage of the GST fusion tag may reduce steric hindrance by this large tag 
as well as eliminate the possibility that CD23 binds to the fusion tag, leading 
to complications in data analysis 
 Produce mutant CD11 I-domains which are locked in a particular affinity 
conformation, e.g. low and high affinity for comparison of binding kinetics 
 Allow association to reach equilibrium and optimise experimental procedures, 
such as immobilization levels, for good kinetic analysis. In particular, the 
immobilization step may be carried out in short ‘bursts’ of a few seconds 
injection to analyse levels of immobilization. If higher levels are required, the 
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step can be repeated, and in this way the immobilization levels can be 
controlled. Flow rate can be optimised, for example McCleverty and 
Liddington (2003) used a flow rate of 5μL/min and Vorup-Jensen (2012) used 
10μL/min for I-domains. 
 If biotinylation is to be used, a 1:1 stoichiometry is recommended to avoid 
over-biotinylation. Blocking of the chip surface with excess biotin after 
immobilization is also recommended to reduce non-specific binding of the 
analyte to the chip surface. 
 Assess all recombinant proteins for oligomer formation using size exclusion 
chromatography. 
 
The mutant CD23 used in this case, where RKC was mutated to AAC, was 
previously found not to bind CD11b or CD11c (Pereira, 2012). Conversely, SPR 
analysis performed in this study showed that the mutant did indeed bind CD11b. This 
requires that the mCD23 be assessed for biological activity. Assessment could be 
performed in silico via 3-D structure modelling or via a simple pull-down assay and 
compared to wild type CD23.  It would be ideal if future studies also assessed the 
binding of single mutant CD23 or CD23-derived synthetic peptides (Pereira, 2012 
and Edkins et al., 2012) to CD11b I-domain as well as CD18 I-Like domain using 
SPR spectroscopy. The use of synthetic peptides gives targeted information of the 
interaction surfaces or key residues involved in binding. 
 
Further characterisation of the interaction between CD23 and the β2 integrins may 
further validate the use of this interaction as a target for therapeutic intervention, 
especially with regard to inflammatory disease.  
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8.1 Supplementary Figures 
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Figure 8.1.1: Structure of CD11c/CD18, integrin αXβ2. Cartoon of αXβ2 molecule in an 
extended model made by adjusting domain interfaces at and near the knees. Domains are 
labelled and assigned specific colours (Xie et al., 2010). 
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Figure 8.1.2: The α-I, β-I, and β-propeller domain interface, and I domain metal-binding sites. 
(A, B) The interface. Representations: disulfides are gold sticks, and glycans are sticks with 
white carbons. Ca2+ and Mg2+ ions are gold and green spheres, respectively. Smaller 
spheres show Ca atoms of conformation-associated epitopes and C-terminal residues. The 
indicated sidechains and backbone carbonyls are shown as sticks. (C) Superposition of 
headpieces from αXβ2(magenta), unliganded-closed αIIbβ3 (Zhu et al., 2008) (yellow) and 
liganded-open (Springer et al., 2008) αIIbβ3 (cyan, with ligand in black).(D) Enlarged view of 
the superposition in (C) showing only αXβ2 (with its ADMIDAS metal as cyan sphere) and the 
ligand and SYMBS, MIDAS, and ADMIDAS metals from liganded-open αIIbβ3 (yellow). (E–G) 
Metal coordination sites, with coordinations dashed. (E) α-I domain MIDAS.(F, G) β-I domain 
metal-binding sites in αXβ2, and unliganded-closed αIIbβ3, respectively (Xie et al., 2010). 
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8.2 Supplementary Alignments and Sensorgrams 
A: DNA and Protein Alignments 
 
 
Optimized 7   TATCTGCGTCCGGGCCAAGCGGCGGCGTTTAATGTGACCTTTCGTCGTGCCAAGGGCTAT 
Original      7TACCTGCGACCAGGCCAGGCAGCAGCGTTCAACGTGACCTTCCGGCGGGCCAAGGGCTAC 
 
Optimized 67  CCGATTGACCTGTACTATCTGATGGATCTGAGCTATTCTATGCTGGATGACCTGCGTAAC 
Original 67   CCCATCGACCTGTACTATCTGATGGACCTCTCCTACTCCATGCTTGATGACCTCAGGAAT 
 
Optimized 127 GTCAAAAAGCTGGGCGGTGATCTGCTGCGTGCACTGAATGAAATTACCGAAAGTGGCCGC 
Original 127  GTCAAGAAGCTAGGTGGCGACCTGCTCCGGGCCCTCAACGAGATCACCGAGTCCGGCCGC 
 
Optimized 187 ATCGGCTTTGGTTCCTTCGTGGATAAAACCGTTCTGCCGTTTGTCAACACGCATCCGGAC 
Original 187  ATTGGCTTCGGGTCCTTCGTGGACAAGACCGTGCTGCCGTTCGTGAACACGCACCCTGAT 
 
Optimized 247 AAGCTGCGTAACCCGTGCCCGAATAAAGAAAAGGAATGTCAGCCGCCATTTGCGTTCCGC 
Original 247  AAGCTGCGAAACCCATGCCCCAACAAGGAGAAAGAGTGCCAGCCCCCGTTTGCCTTCAGG 
 
Optimized 307 CACGTTCTGAAACTGACCAACAATAGCAACCAGTTCCAAACGGAAGTCGGCAAGCAGCTG 
Original 307  CACGTGCTGAAGCTGACCAACAACTCCAACCAGTTTCAGACCGAGGTCGGGAAGCAGCTG 
 
Optimized 367 ATTTCTGGTAATCTGGATGCACCGGAAGGCGGTCTGGACGCAATGATGCAAGTGGCAGCA 
Original 367  ATTTCCGGAAACCTGGATGCACCCGAGGGTGGGCTGGACGCCATGATGCAGGTCGCCGCC 
 
Optimized 427 TGCCCGGAAGAAATCGGTTGGCGTAACGTGACCCGCCTGCTGGTTTTTGCGACGGATGAC 
Original 427  TGCCCGGAGGAAATCGGCTGGCGCAACGTCACGCGGCTGCTGGTGTTTGCCACTGATGAC 
 
Optimized 487 GGTTTTCATTTCGCAGGCGATGGTAAACTGGGCGCTATTCTGACCCCGAATGATGGTCGT 
Original 487  GGCTTCCATTTCGCGGGCGACGGGAAGCTGGGCGCCATCCTGACCCCCAACGACGGCCGC 
 
Optimized 547 TGTCACCTGGAAGACAACCTGTATAAACGCTCAAATGAATTTGATTACCCGTCGGTGGGT 
Original 547  TGTCACCTGGAGGACAACTTGTACAAGAGGAGCAACGAATTCGACTACCCATCGGTGGGC 
 
Optimized 607 CAGCTGGCACATAAACTGGCTGAAAACAATATTCAACCGATCTTCGCGGTCACGTCCCGC 
Original 607  CAGCTGGCGCACAAGCTGGCTGAAAACAACATCCAGCCCATCTTCGCGGTGACCAGTAGG 
 
Optimized 667 ATGGTGAAAACCTACGAAAAGCTGACGGAAATTATCCCGAAAAGCGCCGTTGGTGAACTG 
Original 667  ATGGTGAAGACCTACGAGAAACTCACCGAGATCATCCCCAAGTCAGCCGTGGGGGAGCTG 
 
Optimized 727 TCGGAAGACTCCAGCAATGTCGTCCAACTGATTAAGAATGCCTACAATAAA 
Original 727  TCTGAGGACTCCAGCAATGTGGTCCAACTCATTAAGAATGCTTACAATAAA 
 
Figure A1: DNA alignment of optimized CD18 I-Like Domain to original sequence showing 
optimized codons in red. 
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Optimized 1   YLRPGQAAAFNVTFRRAKGYPIDLYYLMDLSYSMLDDLRNVKKLGGDLLRALNEITESGR 
Original 1    YLRPGQAAAFNVTFRRAKGYPIDLYYLMDLSYSMLDDLRNVKKLGGDLLRALNEITESGR 
 
Optimized 61  IGFGSFVDKTVLPFVNTHPDKLRNPCPNKEKECQPPFAFRHVLKLTNNSNQFQTEVGKQL 
Original 61   IGFGSFVDKTVLPFVNTHPDKLRNPCPNKEKECQPPFAFRHVLKLTNNSNQFQTEVGKQL 
 
Optimized 121 ISGNLDAPEGGLDAMMQVAACPEEIGWRNVTRLLVFATDDGFHFAGDGKLGAILTPNDGR 
Original 121  ISGNLDAPEGGLDAMMQVAACPEEIGWRNVTRLLVFATDDGFHFAGDGKLGAILTPNDGR 
 
Optimized 181 CHLEDNLYKRSNEFDYPSVGQLAHKLAENNIQPIFAVTSRMVKTYEKLTEIIPKSAVGEL 
Original 181  CHLEDNLYKRSNEFDYPSVGQLAHKLAENNIQPIFAVTSRMVKTYEKLTEIIPKSAVGEL 
 
Optimized 241 SEDSSNVVQLIKNAYNK 
Original 241  SEDSSNVVQLIKNAYNK 
 
Figure A2: Protein alignment of optimized CD18 I-Like Domain to original sequence showing 
conservation of the amino acid sequence after codon optimization. 
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B: Additional Sensorgrams 
 
 
 
Figure B1: (A) Sensorgrams depicting the measurement of the dissociation constant (KD) for 
the binding between the CD11b α-I domain (mid-level immobilization) and 25kDa CD23 at 
flow rate 50μL/min for 60s association. Data were fitted to the 1:1 Langmuir model with 
BIAevaluation v3.0.2. (B) Relative residual plot showing the accuracy of fit. X2 ~1.65 
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Figure B2: (A) Sensorgrams depicting the measurement of the dissociation constant (KD) for 
the binding between the CD11b α-I domain (high-level immobilization) and 25kDa CD23 at 
flow rate 50μL/min for 60s association. Data were fitted to the 1:1 Langmuir model with 
BIAevaluation v3.0.2. (B) Relative residual plot showing the accuracy of fit. X2~1.45 
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Figure B3: (A) Sensorgrams depicting the measurement of the dissociation constant (KD) for 
the binding between GST (high-level immobilization) and 25kDa CD23 at flow rate 50μL/min 
for 60s association. Data were fitted to the 1:1 Langmuir model with BIAevaluation v3.0.2. 
(B) Relative residual plot showing the accuracy of fit. X2 ~1.24 
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Figure B4: (A) Sensorgrams depicting the measurement of the dissociation constant (KD) for 
the binding between CD11b α-I domain (mid-level immobilization) and 25kDa CD23 at flow 
rate 100μL/min for 60s association. Data were fitted to the 1:1 Langmuir model with 
BIAevaluation v3.0.2. (B) Relative residual plot showing the accuracy of fit. X2 ~2.4 
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Figure B5: (A) Sensorgrams depicting the measurement of the dissociation constant (KD) for 
the binding between CD11b α-I domain (high-level immobilization) and 25kDa CD23 at flow 
rate 100μL/min for 60s association. Data were fitted to the 1:1 Langmuir model with 
BIAevaluation v3.0.2. (B) Relative residual plot showing the accuracy of fit. X2 ~3.02 
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Figure B6: (A) Sensorgrams depicting the measurement of the dissociation constant (KD) for 
the binding between GST (high-level immobilization) and 25kDa CD23 at flow rate 
100μL/min for 60s association. Data were fitted to the 1:1 Langmuir model with 
BIAevaluation v3.0.2. (B) Relative residual plot showing the accuracy of fit. X2 ~2.19 
